

FORMATO EUROPEO PER IL CURRICULUM VITAE



INFORMAZIONI DEMOGRAFICHE

Nome e Cognome: Giuseppe Sanguineti

Qualifica corrente: Dirigente Medico con incarico di Direzione di Struttura Complessa, Unita' Operativa Complessa di Oncologia Radioterapica, Istituto Nazionale Tumori Regina Elena, ROMA (IT)

Dati personali:

Data di nascita: 29 Luglio 1964

Luogo di nascita: Aosta (IT)

Indirizzo lavoro: Oncologia Radioterapica, Via Elio Chianesi, 53, 00144 Roma, Italy

Telefono: +39 06 5266 3010; +39 5266 4680

E-mail: giuseppe.sanguineti@ifo.it

Educazione e Training

B.S.	Oct 1977– July 1982	Liceo Scientifico "Istituto Arecco", Genoa, Italy
Laurea	Oct 1982– Nov 1988	facoltà di Medicina e Chirurgia, Università di Genova, Italia
Internship	Nov 1988–Oct 1989	University of Genoa, Italy
Specialità #1	Nov 1989–Oct 1993	Radiation Oncology, University of Genoa, Italy
Fellowship	July 1994– June 1995	Department of Radiation Therapy, M.D. Anderson Cancer Center, Houston, Texas, U.S.A.
Specialità #2	Nov 1993– Ott 1997	Oncologia Clinica, Università di Genova, Italia
Specialità #3	Genn 2001– Lug 2007	Board Certification in Radiation Oncology USA

Esperienza Professionale:

Assistente/Aiuto	Genn 1990–Genn 2002	UOC Radioterapia Oncologica, Istituto per la Ricerca sul Cancro, Genova, Italia
Professore Associato	Genn 2002–Lug 2007	Reperto di Radioterapia, Università del Texas Medical Branch, Galveston, TX, USA
Professore Associato	Ago 2007– Mag 2011	Reperto di Radioterapia, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Direttore	Giu 2011 – Ott 2013	Reperto di Radioterapia, Ospedale Sacro Cuore, Negrar (VR), Italia
Direttore	Ago 2015–Dic 2021	Dipartimento di Tecnologia Avanzata e Ricerca, IRCCS Istituto Tumori Regina Elena, Roma
Direttore	Ott 2013–oggi	UOC di Radioterapia, IRCCS Istituto Tumori Regina Elena, Roma

Pubblicazioni

Peer-reviewed original research articles

1. Merlano M., Vitale V., Rosso R., Benasso M., Corvo' R., Cavallari M., **Sanguinetti G.**, Bacigalupo A., Badellino F., Margarino G., Brema F., Pastorino G., Marziano C., Grimaldi A., Scasso F., Sperati G., Pallestrini E., Garaventa G., Accomando E., Cordone C., Comella C., Daponte A., Rubagotti A., Bruzzi P., Santi L.: Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. *New Engl J Med* 327: 1115-1121,1992
2. **G. Sanguinetti**, F. B. Geara, A.S. Garden, S.L. Tucker, K.K. Ang, W.H. Morrison, L.J. Peters: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. *Int. J. Radiation Oncology Biol. Phys.* Vol. 37, N. 5: 985-996, 1997
3. F.B. Geara, B.S. Glisson, **G.Sanguinetti**, S.L. Tucker, A.S. Garden, K.K. Ang, S.M. Lippman, G.L. Clayman, H. Goepfert, L.J. Peters, W.K. Hong: Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Results of a matched cohort study. *Cancer* 79 (7):1279-1286, 1997
4. F.B. Geara, **G. Sanguinetti**, S.L. Tucker, A.S.Garden,K.K. Ang, W.H. Morrison, L. J. Peters: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. *Radiotherapy & Oncology* 43:53-61, 1997
5. **Sanguinetti G**, Corvò R, Vitale V, Lionetto R, Foppiano F. Post-operative radiotherapy for head and neck squamous cell carcinomas: feasibility of a biphasic accelerated treatment schedule. *Int J Rad Oncol Biol Phys* 36:1147-1153, 1996
6. Benasso M, Bonelli L, Numico G, Corvo R, **Sanguinetti G**, Rosso R, Vitale V, Merlano M. Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients. *Annals of Oncology* 8: 773-779, 1997
7. Corvò R, Giaretti W, **Sanguinetti G**, Geido E, Bacigalupo A, Orecchia R, Benasso M, Numico GM, Merlano M, Margarino G, Vitale V. Chemotherapy as an alternative ro radiotherapy alone in fast proliferating head and neck squamous cell carcinomas. *Clin Cancer Res* 3:1993-1997, 1997
8. Corvo R, Giaretti W, Geido E, **Sanguinetti G**, Orecchia R, Scala M, Garaventa G, Mora E, Vitale V. Cell kinetics and tumor regression during radiotherapy in head and neck squamous cell carcinomas. *Int J Cancer* 68:151-155, 1996
9. **G Sanguinetti**, R Corvo', M Benasso, G Margarino, MP Sormani, F Roncallo, P Mereu, A Bacigalupo, V Vitale. Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer. *Head & Neck* 1999 May;21(3):223-8
10. **G Sanguinetti**, R Corvò, MP Sormani, M Benasso, G Numico, A Bacigalupo, R Rosso, V Vitale. Chemotherapy Alternated with Radiotherapy in the Treatment of Advanced Head and Neck Carcinoma: Predictive Factors of Outcome. *Int J Radiat Oncol Biol Phys* 1999 Apr 1;44(1):139-47
11. Spriano G, Antognoni P, **Sanguinetti G**, Sormani M, Richetti A, Ameli F, Piantanida R, Luraghi R, Magli A, Corvo R, Tordiglione M, Vitale V. Laryngeal long-term morbidity after supraglottic laryngectomy and postoperative radiation therapy. *Am J Otolaryngol* 2000 Jan-Feb;21(1):14-21
12. Corvo R, Paoli G, Giaretti W, **Sanguinetti G**, Geido E, Benasso M, Margarino G, Vitale V. Evidence of cell kinetics as predictive factor of response to radiotherapy alone or chemoradiotherapy in patients with advanced head and neck cancer. *Int J Radiat Oncol Biol Phys* 47(1): 47-63, 2000
13. M Benasso, **Sanguinetti G**, I Ricci, M D'Amico, GM Numico, R Corvò, V Vitale, R Rosso. Induction chemotherapy followed by alternating chemotherapy in advanced nasopharyngeal carcinoma. *Br J Cancer* 83(11): 1437-1442 , 2000
14. **Sanguinetti G**, Del Mastro L, Guenzi M, Ricci P, Cavallari M, Canavese G, Venturini M. Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery. *Ann Oncol.* 2001 Mar;12(3):373-8.
15. Fiorino C, Valvassori V, **Sanguinetti G**, Bianchi C, Cattaneo GM, Piazzola A, Cozzarini C. Impact of inter-institute variability in rectum contouring on 3D treatment planning dose/volume information. *Radiotherapy and Oncology* 63(3):249-55, 2002
16. Corvò R, Benasso M, **Sanguinetti G**, Ricci I, Merlano M, Rosso R, Vitale V. Alternating chemoradiotherapy versus partly accelerated radiotherapy: results from a phase III study. *Cancer* 2001;92:2856-67
17. **Sanguinetti G**, Agostinelli S, Foppiano F, Franzone P, Garelli S, Marcenaro M, Orsatti M, Vitale V. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. *Br J Cancer* 2002 ; 86(12):1843-7.
18. Fiorino C., Cozzarini C, Vavassori V, **Sanguinetti G**, Bianchi C., Cattaneo G.M., Foppiano F, Magli A., Piazzolla A. Significant correlation between DVH and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. *Radiotherapy and Oncology* 2002, 64(1):1;
19. **Sanguinetti G**, Franzone P, Culp L, Marcenaro M, Barra S, Colman M, Vitale V. Radiotherapy after prostatectomy. *Tumori* 2002;88(6):445-52
20. **G. Sanguinetti**, M. Marcenaro, P. Franzone, F. Foppiano, V Vitale. Neoadjuvant Androgen Deprivation And Prostate Gland Shrinkage During Conformal Radiotherapy. *Radiotherapy and Oncology* 2003;66(2):151-7
21. **Sanguinetti G**, Marcenaro M, Franzone P, Tognoni P, Barra S, Vitale V. Is there a `curative` role of radiotherapy for clinically localized hormone refractory prostate cancer? *Am J Clin Oncol* 2004 Jun;27(3):264-8.
22. **G Sanguinetti**, P Franzone, M Marcenaro, F Foppiano, V Vitale. Sucralfate versus Mesalazine versus Hydrocortisone in the Prevention of Acute Radiation Proctitis during Conformal Radiotherapy for Prostate Carcinoma: a Randomized Study, *Strahlenther Onkol* 2003; 179(7):464-70

23. C Fiorino, **G Sanguineti**, C Cozzarini, G Fellin, F Foppiano, L Menegotti, A Piazzolla, V Vavassori, R Valdagni. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2003; 57(4): 953–62
24. Benasso M, Corvo R, Ponzanelli A, **Sanguineti G**, Ricci I, Pallestrini E, Santelli A, Vitale V, Rosso R. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. *Ann Oncol.* 2004 Apr;15(4):646–52
25. **Sanguineti G**, Culp LR, Endres EJ, Bayouth JE. Are neck nodal volumes drawn on CT slices covered by standard three-field technique? *Int J Radiat Oncol Biol Phys.* 2004;59(3):725–42.
26. T. Rancati, C. Fiorino, G. Gagliardi, G.M. Cattaneo, **G. Sanguineti**, V. Casanova Borca, C. Cozzarini, G. Fellin, F. Foppiano, G. Girelli, L. Menegotti, A. Piazzolla, V. Vavassori, R. Valdagni. Fitting late rectal bleeding data using different NTCP models: results from an Italian multicentric study (AIROPROS0101). *Radiotherapy & Oncology* 2004 Oct;73(1):21–32
27. **G Sanguineti**, P Castellone, F Foppiano, P Franzone, M Marcenaro, P Tognoni, A Bolognesi, G Luca Ceresoli, C Fiorino. ANATOMICAL VARIATIONS DUE TO RADICAL PROSTATECTOMY: IMPACT ON TARGET VOLUME DEFINITION AND DOSE-VOLUME PARAMETERS OF RECTUM AND BLADDER. *Strahlentherapie und Onkologie* 2004;180(9):563–72
28. **G Sanguineti**, A Richetti, M Bignardi, R Corvo', P Gabriele, MP Sormani, P Antognoni. Accelerated Versus Conventional Fractionated Postoperative Radiotherapy for Advanced Head and Neck Cancer: Results of a Multicenter Phase III Study. *Int J Radiat Oncol Biol Phys*, 2005; 61(3):762–771
29. Fiorino C, Foppiano F, Franzone P, Broggi S, Castellone P, Marcenaro M, Calandrino R, **Sanguineti G**. Rectal and bladder motion during conformal radiotherapy after radical prostatectomy. *Radiother Oncol.* 2005 Feb;74(2):187–95.
30. Cavey ML, Bayouth JE, Colman M, Endres EJ, **Sanguineti G**. IMRT to escalate the dose to the prostate while treating the pelvic nodes. *Strahlenther Onkol.* 2005 Jul;181(7):431–441
31. **Sanguineti G**; Cavey ML; Endres EJ; Brandon GG; Bayouth, JE. IS IMRT NEEDED TO SPARE THE RECTUM WHEN PELVIC LYMPH NODES ARE PART OF THE INITIAL TREATMENT VOLUME FOR PROSTATE CANCER? *Int J Radiat Oncol Biol Phys* 2006 Jan 1;64(1):151–60
32. **Sanguineti G**, Cavey ML, Endres EJ, Barra S, Parker BC, Marcenaro M, Colman M, Agostinelli S, Foppiano F, Vitale V. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? *Strahlenther Onkol.* 2006 Sep;182(9):543–549.
33. **Sanguineti G**, Endres E, Gunn B, Parker B. Is there a `mucosa sparing` benefit of IMRT for HN cancer? *Int J Radiat Oncol Biol Phys.* 2006 Nov 1;66(3):931–8.
34. **Sanguineti G**, Adapala P, Endres E, Brack C, Fiorino C, Sormani MP, Parker B. Dosimetric predictors of laryngeal edema. *Int J Radiat Oncol Biol Phys* 2007;68(3):741–9.
35. **Sanguineti G**, Endres EJ, Parker BC, Biquart C, Little M, Chen G, Berilgen J. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. *Acta Oncol.* 2008;47(2):301–10.
36. NG Rao, **G Sanguineti**, G Chaljub, SD Newlands, S Qiu. Neck levels that are negative on initial CT do not need to be dissected after definitive radiation therapy with or without chemotherapy. *Head Neck.* 2008 Aug;30(8):1090–8
37. **Sanguineti G**; Gunn, GB; Endres, EJ; Chaljub, G; Cheruvu, P; Parker, B. Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2008 Nov 1;72(3):737–46
38. **Sanguineti G**; Little M; Endres EJ; Sormani MP; Parker B. Comparison of 3 strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. *Radiother Oncol.* 2008 Jul;88(1):95–101.
39. **Sanguineti G**, Califano J, Stafford E, Fox J, Koch W, Tufano R, Sormani MP, Forastiere A. Defining the Risk of Involvement for Each Neck Nodal Level in Patients With Early T-Stage Node-Positive Oropharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys* 2009 Aug 1;74(5):1356–64.
40. **G Sanguineti**; EJ Endres; MP Sormani; B Parker. Dosimetric predictors of diarrhea during radiotherapy for prostate cancer. *Strahlenther Onkol.* 2009 Jun;185(6):390–6.
41. A Eisbruch, J Harris, AS Garden, CKS Chao, W Straube, PM Harari, **G Sanguineti**, CU Jones, WR Bosch, KK Ang. Multi-institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early Stage Oropharyngeal Cancer (RTOG 00-22). *Int J Radiat Oncol Biol Phys.* 2010 Apr;76(5):1333–8
42. Rancati T, Fiorino C, **Sanguineti G**. NTCP MODELING OF SUBACUTE/LATE LARYNGEAL EDEMA SCORED BY FIBEROPTIC EXAMINATION. *Int J Radiat Oncol Biol Phys.* 2009 Nov 1;75(3):915–23
43. KM Pattani, J Califano, **G Sanguineti**. Level V involvement in patients with early T-stage, node-positive oropharyngeal carcinoma. *Laryngoscope* 2009 Nov;119(11):2165–9
44. Gunn GB, Endres EJ, Sormani MP, **Sanguineti G**. A Phase I-II Study of Accelerated Hyperfractionated IMRT Alone for Intermediate T-Stage Oropharyngeal Carcinoma. *Strahlenther Onkol.* 2010 Sep;186(9):489–95
45. Bayouth JE, Pena J, Culp L, Brack C, **Sanguineti G** Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients. *Med Dosim.* 2008 Autumn;33(3):180–90.
46. Wu B, Ricchetti F, **Sanguineti G**, Kazhdan M, Simari P, Chuang M, Taylor R, Jacques R, McNutt T. Patient geometry-driven information retrieval for IMRT treatment plan quality control. *Med Phys.* 2009 Dec;36(12):5497–505.
47. Broggi S, Fiorino C, Dell'Oca I, Dinapoli N, Paiusco M, Muraglia A, Maggiulli E, Ricchetti F, Valentini V, **Sanguineti G**, Cattaneo GM, Di Muzio N, Calandrino R. A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. *Radiother Oncol.* 2010 Feb;94(2):206–12.
48. **Sanguineti G**, Gunn GB, Parker BC, Endres EJ, Zeng J, Fiorino C. Weekly Dose-Volume Parameters of Mucosa and Constrictor Muscles Predict the Use of Percutaneous Endoscopic Gastrostomy During Exclusive Intensity-Modulated Radiotherapy for Oropharyngeal Cancer. *Int J Radiat Oncol Biol Phys* 2011 Jan 1;79(1):52–9.
49. F Ricchetti, B Wu, T McNutt, J Wong, A Forastiere, S Marur, H Starmer, **G Sanguineti**. Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. *Int J Radiat Oncol Biol Phys.* 2011 May 1;80(1):161–8.

50. S Clemente, B Wu, V Fusco, **G Sanguineti**, F Ricchetti, J Wong, T McNutt. Smart Arc-based Volumetric Modulated Arc Therapy for Oropharyngeal Cancer: A Dosimetric Comparison with both Intensity Modulated Radiation Therapy and Helical Tomotherapy. *Int J Radiat Oncol Biol* 2011 Jul 15;80(4):1248-55
51. E Tryggstad, M Christian, E Ford, C Kut, Y Le, **G Sanguineti**, D Song, L Kleinberg. Inter- and intra-fraction patient positioning uncertainties for intra-cranial radiotherapy: a study of four frameless, thermoplastic mask-based immobilization strategies using daily cone-beam CT. *Int J Radiat Oncol Biol* 2011 May 1;80(1):281-90
52. B WU, F RICCHETTI, **G SANGUINETI**, M KAZHDAN, P SIMARI, R JACQUES, R TAYLOR, T MCNUTT. A DATA-DRIVEN APPROACH TO GENERATING ACHIEVABLE DVH OBJECTIVES IN IMRT TREATMENT PLANNING. *Int J Radiat Oncol Biol Phys.* 2011 Mar 15;79(4):1241-7
53. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiat WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, **Sanguineti G**, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F. Head and neck cancers. *J Natl Compr Canc Netw.* 2011;9(6):596-650.
54. **Sanguineti G**, Sormani MP, Marur S, Gunn GB, Rao N, Cianchetti M, Ricchetti F, McNutt T, Wu B, Forastiere A. Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis during Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer. *Int J Radiat Oncol Biol Phys.* 2012;83(1):235-42
55. Starmer H, **Sanguineti G**, Marur S, Gourin CG. Multidisciplinary head and neck cancer clinic and adherence with speech pathology. *Laryngoscope.* 2011 Oct;121(10):2131-5.
56. **G Sanguineti**, R Corvò. Nasopharyngeal carcinoma: state of the art and new perspectives (review). *Oncol Rep* 1999 Mar-Apr;6(2):377-91
57. **G Sanguineti**, P Bossi, A Pou, L Licitra. Timing of Chemoradiotherapy and Patient Selection for Locally Advanced Nasopharyngeal Carcinoma. *Clin Oncol (R Coll Radiol).* 2003; 15(8): 451-60 (review).
58. C Fiorino, R Valdagni, T Rancati, **G. Sanguineti**. DOSE-VOLUME EFFECTS FOR NORMAL TISSUES IN EXTERNAL RADIOTHERAPY: PELVIS. *Radiother Oncol.* 2009 Nov;93(2):153-67. (educational review)
59. **Sanguineti G**, DeWeese T. Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done? *Oncology (Williston Park)* 2009 Apr 15;23(4):390, 393 (invited commentary)
60. Corvo' R., Giaretti W., **Sanguineti G.**, Geido E., Orecchia R., Barra S., Margarino G., Bacigalupo A., Vitale V.: Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. *Int J Radiat Biol Phys* 27(5):1165-1172,1993
61. Corvò R, Antognoni P, **Sanguineti G**. Biological predictors of response to radiotherapy in head and neck cancer: recent advances and emerging perspectives. *Tumori.* 2001 Nov-Dec;87(6):355-63
62. Gourin CG, Forastiere AA, **Sanguineti G**, Marur S, Koch WM, Bristow RE. Volume-based trends in laryngeal cancer surgery. *Laryngoscope.* 2011 Jan;121(1):77-84.
63. Gourin CG, Forastiere AA, **Sanguineti G**, Koch WM, Marur S, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care. *Laryngoscope.* 2011 Apr;121(4):746-52
64. Gourin CG, Forastiere AA, **Sanguineti G**, Marur S, Koch WM, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care. *Laryngoscope.* 2011 Jan;121(1):85-90.
65. Gourin CG, Forastiere AA, **Sanguineti G**, Marur S, Koch WM, Bristow RE. Volume-based trends in surgical care of patients with oropharyngeal cancer. *Laryngoscope.* 2011 Apr;121(4):738-45
66. Culp L, Pou A, Jones D, Bayouth J, **Sanguineti G**. A Case of Radiation Recall Mucositis Associated with Docetaxel. *Head Neck.* 2004 Feb;26(2):197-200
67. Gunn GB, Patel AJ, Gallegos J, Anderson KE, Hatch SS, **Sanguineti G**. Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a case report and literature review. *Head Neck* 2010 Aug;32(8):1112-7. (review)
68. **G Sanguineti**, F Ricchetti, B Wu, N Agrawal, C Gourin, H Agbahiwe, S Marur, S Clemente, T McNutt, A Forastiere. Volumetric change of HPV-related neck lymph nodes before, during and shortly after IMRT. *Head and Neck* 2012;34(11):1640-7
69. Guenzi M., **Sanguineti G.**, Botto F., Ghiso G., Andreucci L., Vitale V.: A proposal for the treatment technique for the breast and regional lymphnodes in patients with conservatively operated neoplasms. *Radiol Med* 4 (suppl 1):77-80,1990
70. Guenzi M., Scarpati D., Corvo' R., **Sanguineti G.**, Gardin G., Conte P.F., Vitale V.: The role of radiotherapy in the multimodal treatment of locally advanced breast carcinoma. *Radiol Med* 79: 534-9,1990
71. Corvo' R., Scarpati D., **Sanguineti G.**, Vitale V.: The predictability of the radiotherapy response in epidermoid tumors of the head and neck. A review of the literature and mathematical models for choosing the fractionated doses. *Radiol. Med.* 79:520-9,1990
72. Margarino G., Scala M., Schenone G., Mereu P., Corvo' R., **Sanguineti G.**, Giaretti W., Geido E., Orecchia R., Meszaros P., Badellino F.: Cell kinetic analysis and treatment planning in epidermoid tumors of the head and neck. *Acta Otorhinolaryngol Ital* 12:421-33, 1992
73. **Sanguineti G**, Orsatti M, Sormani MP, Canobbio L, Curotto A, Tognoni P, Giudici S, Franzone P, Boccardo F, Vitale V. Predictive factors for outcome in invasive bladder cancer treated with alternating cheoradiotherapy. *Cancer J Sci Am* 3:213-223, 1997
74. Corvo' R., Giaretti W., **Sanguineti G.**, Geido E., Bacigalupo A., Franzone P., Mereu P., Garaventa G., Barbieri M., Vitale V.: The prognostic role of the parameters of cellular kinetics in head and neck tumors treated solely by radiotherapy. *Radiol Med* 86:135-42,1993
75. Corvo' R., **Sanguineti G.**, Scala M., Garaventa G., Santelli A., Barbieri M., Vitale V.: Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy. *Tumori* 80:135-138, 1994

76. **Sanguineti G.**, Corvo' R., Frascio F., Vitale V.: Accelerated radiotherapy according to the concomitant boost technique in patients affected by head and neck squamous cell carcinoma. *Radiol Med* 88: 650–656, 1994
77. Sosa M, **Sanguineti G.** External beam radiotherapy as definitive treatment for prostate cancer. *Minerva Urol Nefrol.* 2003 Dec;55(4):263–275 (invited review)
78. Benasso M., Corvo' R., Numico G., Cavallari M., Blengio F., **Sanguineti G.**, Rosso M., Merlano M. Concomitant administration of two standard regimens of chemotherapy and radiotherapy in advanced squamous carcinoma of the head and neck: a feasibility study. *Anticancer Research* 15:2651–2654, 1995
79. Corvo' R., Giaretti W., **Sanguineti G.**, Geido E., Orecchia R., Guenzi M., Margarino G., Bacigalupo A., Garaventa G., Barbieri M., Vitale V.: In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. *J Clin Oncol* 13: 1843–1850, 1995
80. **Sanguineti G.**, Forastiere AA. Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer. *Nat Clin Pract Oncol.* 2008 Dec;5(12):694–5 (invited commentary).
81. **Sanguineti G.**, M Benasso, R Corvò, M Marcenaro, I Ricci, M D'Amico, F Mora, V Vitale. Lack of a time factor in alternating chemoradiotherapy for advanced head and neck squamous cell carcinoma. *Tumori* 87 (1): 17–21, 2001
82. **Sanguineti G.**, Foppiano F, Marcenaro M, Roncallo F, Corvò R, Ameli F, Vitale V. On the Delineation of the Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) for Head and Neck Squamous Cell Carcinomas. *Tumori* 87(3): 254–259, 2001
83. R. Corvo', **G. Sanguineti**, V. Vitale, A. Bacigalupo, G. Margarino, M. Benasso, G.M. Numico, W. Giaretti: In vivo cell kinetics in elderly patients affected by squamous cell carcinoma of the head and neck. *Rays*, 22 suppl. n.1, 69–72, 1997
84. **Sanguineti G.**, Sormani MP, Benasso M, Corvo' R, Foppiano F, Ricci I, Marcenaro M, Rosso R, Vitale V. Late local treatment morbidity after accelerated radiotherapy alone or alternating chemoradiotherapy for advanced head and neck carcinoma. *Tumori.* 2002; 88(4):313–20
85. Corvò R, **Sanguineti G.**, Benasso M. Biological and clinical implications for multimodality treatment in patients affected by squamous cell carcinoma of the head and neck. *Tumori* 84: 217–222, 1998
86. Corvo R, Margarino G, **Sanguineti G.**, Geido E, Scala M, Mereu P, Cavallari M, Bonanno S, Garaventa G, Barbieri M, Giaretti W. Cell kinetic analysis in patients affected by squamous cell carcinoma of the head and neck treated with primary surgery and adjuvant radiotherapy. *Tumori* 86: 53–58, 2000
87. Benasso M, Merlano M, **Sanguineti G.**, Corvò R, Numico GM, Ricci I, Pallestrini E, Santelli A, Vitale V, Marchetti G, Rosso R. Gemcitabine, Cisplatin and radiation in advanced unresectable squamous cell carcinoma of the head and neck: a feasibility study. *Am J Clin Oncol* 24:618–622, 2001
88. Busto G, Corvò R, Ricci I, **Sanguineti G.**, Benasso M. New chemoradiotherapy combinations in head and neck cancer. *Expert Rev Anticancer Ther* 2001; 1(1): 111–115
89. Bignardi M, Antognoni P, **Sanguineti G.**, Magli A, Molteni M, Merlotti A, Richetti A, Tordiglione M, Conte L, Magno L. Hyperfractionated radiotherapy for T2N0 glottic carcinoma: a retrospective analysis at 10 years follow-up in a series of 60 consecutive patients *Tumori.* 2004;90(3):317–23
90. Wu B, McNutt T, Zahurak M, Simari P, Pang D, Taylor R, **Sanguineti G.** Fully Automated Simultaneous Integrated Boosted-Intensity Modulated Radiation Therapy Treatment Planning Is Feasible for Head-and-Neck Cancer: A Prospective Clinical Study. *Int J Radiat Oncol Biol Phys.* 2012; 84(5):e647-53
91. Fiorino C, Rizzo G, Scalco E, Broggi S, Belli ML, Dell'oca I, Dinapoli N, Ricchetti F, Rodriguez AM, Di Muzio N, Calandrino R, **Sanguineti G.**, Valentini V, Cattaneo GM. Density variation of parotid glands during IMRT for head-neck cancer: Correlation with treatment and anatomical parameters. *Radiother Oncol.* 2012;104(2):224–9.
92. Russi EG, Corvò R, Merlotti A, Alterio D, Franco P, Pergolizzi S, De Sanctis V, Ruo Redda MG, Ricardi U, Paiar F, Bonomo P, Merlano MC, Zurlo V, Chiesa F, **Sanguineti G.**, Bernier J. Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: Review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. *Cancer Treat Rev.* 2012; 38(8):1033-49
93. Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, **Sanguineti G.**, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf G, Worden F; National Comprehensive Cancer Network. Mucosal melanoma of the head and neck. *J Natl Compr Canc Netw.* 2012 Mar;10(3):320–38.
94. **Sanguineti G.**, Ricchetti F, Thomas O, Wu B, McNutt T. Pattern and predictors of volumetric change of parotid glands during intensity modulated radiotherapy. *Br J Radiol.* 2013;86(1031):20130363. Epub 2013 Sep 12
95. **Sanguineti G.**, Ricchetti F, McNutt T, Wu B, Fiorino C. Dosimetric Predictors of Dysphonia after Intensity-modulated Radiotherapy for Oropharyngeal Carcinoma. *Clin Oncol (R Coll Radiol).* 2013 Aug 28.
96. Lin BM, Wang H, D'Souza G, Zhang Z, Fakhry C, Joseph AW, Drake VE, **Sanguineti G.**, Westra WH, Pai SI. Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. *Cancer.* 2013 Oct 1;119(19):3462–71.
97. **Sanguineti G.**, Rao N, Gunn B, Ricchetti F, Fiorino C. Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer. *Radiother Oncol.* 2013;107(3):300–4.
98. Wu B, Pang D, Simari P, Taylor R, **Sanguineti G.**, McNutt T. Using overlap volume histogram and IMRT plan data to guide and automate VMAT planning: a head-and-neck case study. *Med Phys.* 2013;40(2):021714
99. Chan JY, **Sanguineti G.**, Richmon JD, Marur S, Gourin CG, Koch W, Chung CH, Quon H, Bishop JA, Aygun N, Agrawal N. Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. *Arch Otolaryngol Head Neck Surg.* 2012;138(11):1040–6.

100. Scalco E, Fiorino C, Cattaneo GM, Sanguineti G, Rizzo G. Texture analysis for the assessment of structural changes in parotid glands induced by radiotherapy. *Radiother Oncol*. 2013 Oct 31.
101. Russi EG, Sanguineti G, Chiesa F, Franco P, Succo G, Merlotti A, Ansarin M, Melano A, Alterio D, Pergolizzi S, Buglione M, Reali A, Ricardi U, Corvò R. Is there a role for postoperative radiotherapy following open partial laryngectomy when prognostic factors on the pathological specimen are unfavourable? A survey of head and neck surgical/radiation oncologists. *Acta Otorhinolaryngol Ital*. 2013 Oct;33(5):311–319. Review.
102. Sanguineti G, Pai S, Agbahiwe H, Ricchetti F, Westra W, Sormani MP, Clemente S, Califano J. HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. *Acta Oncol*. 2014 May;53(5):662–8
103. Belli ML, Scalco E, **Sanguineti G**, Fiorino C, Broggi S, Dinapoli N, Ricchetti F, Valentini V, Rizzo G, Cattaneo GM. Early changes of parotid density and volume predict modifications at the end of therapy and intensity of acute xerostomia. *Strahlenther Onkol*. 2014 Oct;190(11):1001–7
104. Broggi S, Scalco E, Fiorino C, Belli ML, Sanguineti G, Ricchetti F, Dell'Oca I, Dinapoli N, Valentini V, Di Muzio N, Cattaneo GM, Rizzo G. The Shape of Parotid DVH Predicts the Entropy of Gland Deformation During IMRT for Head and Neck Cancers. *Technol Cancer Res Treat*. 2014 Jun 16.
105. Pellini R, Manciocco V, Turri-Zanoni M, Vidiri A, Sanguineti G, Marucci L, Sciuto R, Covello R, Sperduti I, Kayal R, Anelli V, Pichi B, Mercante G, Spriano G. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease. *J Craniomaxillofac Surg*. 2014 Dec;42(8):1834–9
106. Pota M, Scalco E, Sanguineti G, Belli ML, Cattaneo GM, Esposito M, Rizzo G. Likelihood-fuzzy analysis of parotid gland shrinkage in radiotherapy patients. *Stud Health Technol Inform*. 2014;207:360–9.
107. Merlotti A, Alterio D, Vigna-Taglianti R, Muraglia A, Lastrucci L, Manzo R, Gambaro G, Caspiani O, Miccichè F, Deodato F, Pergolizzi S, Franco P, Corvò R, Russi EG, Sanguineti G. Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology – head and neck working group. *Radiat Oncol*. 2014 Dec 29;9(1):1165.
108. Sanguineti G, Ricchetti F, Wu B, McNutt T, Fiorino C. Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution. *Radiat Oncol*. 2015 Jan 17;10(1):19.
109. Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, Spadola Bissetti M, Numico G, Gava A, Orlandi E, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, Licitra L, **Sanguineti G**, Langendijk JA, Murphy B. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. *Crit Rev Oncol Hematol*. 2015
110. Belli ML, Broggi S, Scalco E, Cattaneo GM, Dell'Oca I, Logghe G, Moriconi S, **Sanguineti G**, Valentini V, Di Muzio N, Fiorino C, Calandrino R. Analysis of serial CT images for studying the RT effects in head-neck cancer patients. *Conf Proc IEEE Eng Med Biol Soc*. 2015 Aug;2015:5235–8
111. Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, Dattilo R, Bartucci M, Vincenzoni C, Mariani L, Vizza E, **Sanguineti G**, Gadducci A, Vitale I, Barba M, De Maria R, Mottolese M, Maugeri-Saccà M. DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. *PLoS One*. 2016 Mar 1;11(3):e0149872.
112. De Sanctis V, Bossi P, **Sanguineti G**, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendijk JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. *Crit Rev Oncol Hematol*. 2016 Apr;100:147–66.
113. Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Saccà M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, **Sanguineti G**, Giordano A, De Maria R, Venuti A. Targeting Immune Response with Therapeutic Vaccines in Premalignant Lesions and Cervical Cancer: Hope or Reality from Clinical Studies. *Expert Rev Vaccines*. 2016 Apr 11.
114. Landoni V, Fiorino C, Cozzarini C, **Sanguineti G**, Valdagni R, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. *Phys Med*. 2016 Apr 8. pii: S1120-1797(16)00527-5.
115. Strigari L, Pinnarò P, Carlini P, Torino F, Strolin S, Minosse S, **Sanguineti G**, Benassi M. Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. *Crit Rev Oncol Hematol*. 2016 Apr 22. pii: S1040-8428(16)30074-9.
116. Pinnarò P, Giordano C, Farneti A, Strigari L, Landoni V, Marucci L, Petrongari MG, **Sanguineti G**. Impact of Sequencing Radiation Therapy and Chemotherapy on Long-Term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15-Year Follow-Up. *Int J Radiat Oncol Biol Phys*. 2016 Mar 19.
117. Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Filippo SD, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Lauro LD, **Sanguineti G**, Benedetto AD, Giordano A, Vici P. Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab: The DECT trial. *J Cell Physiol*. 2016 May 17
118. Buglioni S, Vici P, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, Vincenzoni C, Mariani L, Vizza E, Venuti A, **Sanguineti G**, Gadducci A, Barba M, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. *Oncoimmunology*. 2016 Mar 28;5(6):e1160187.
119. **Sanguineti G**, Arcidiacono F, Landoni V, Saracino BM, Farneti A, Arcangeli S, Petrongari MG, Gomellini S, Strigari L, Arcangeli G. Macroscopic Hematuria After Conventional or Hypofractionated Radiation Therapy: Results From a Prospective Phase 3 Study. *Int J Radiat Oncol Biol Phys*. 2016 May 25
120. Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A, Sciacchitano S, Giordano C, Pinnarò P, **Sanguineti G**, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado

- G, Vizza E, Giannini G, Soddu S. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. *J Exp Clin Cancer Res.* 2016 Sep 6;35(1):135. doi: 10.1186/s13046-016-0410-3.
121. Scalco E, Marzi S, Sanguineti G, Vidiri A, Rizzo G. Characterization of cervical lymph-nodes using a multi-parametric and multi-modal approach for an early prediction of tumor response to chemo-radiotherapy. *Phys Med.* 2016 Sep 14. pii: S1120-1797(16)30923-1. doi: 10.1016/j.ejmp.2016.09.003.
 122. Marzi S, Piludu F, Forina C, **Sanguineti G**, Covello R, Spriano G, Vidiri A. Correlation Study between Intravoxel Incoherent Motion MRI and Dynamic contrast-enhanced MRI in Head and Neck Squamous Cell Carcinoma: Evaluation in Primary Tumors and Metastatic Nodes. *Magn Reson Imaging.* 2016 Oct 11.
 123. Wu B, Kusters M, Kunze-Busch M, Dijkema T, McNutt T, Sanguineti G, Bzdusek K, Dritschilo A, Pang D. Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE). *Radiother Oncol.* 2017 Feb 12.
 124. Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Garden AS, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncol.* 2017 Sep;18(9):1221-1237. doi: 10.1016/S1470-2045(17)30458-8. Epub 2017 Jul 27. PMID: 28757375
 125. Sini C, Noris Chiorda B, Gabriele P, **Sanguineti G**, Morlino S, Badenchini F, Cante D, Carillo V, Gaetano M, Giandini T, Landoni V, Maggio A, Perna L, Petrucci E, Sacco V, Valdagni R, Rancati T, Fiorino C, Cozzarini C. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects. *Radiother Oncol.* 2017 Jul 21. pii: S0167-8140(17)32458-1. doi: 10.1016/j.radonc.2017.07.005. [Epub ahead of print]
 126. Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carboognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, **Sanguineti G**, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting. *J Cell Physiol.* 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27. PMID: 28710865
 127. Marzi S, Piludu F, **Sanguineti G**, Marucci L, Farneti A, Terrenato I, Pellini R, Benevolo M, Covello R, Vidiri A. The prediction of the treatment response of cervical nodes using intravoxel incoherent motion diffusion-weighted imaging. *Eur J Radiol.* 2017 Jul;92:93-102. doi: 10.1016/j.ejrad.2017.05.002. Epub 2017 May 2.
 128. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Giulia MD, Marolla P, **Sanguineti G**, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *Oncotarget.* 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22. PMID: 28915642
 129. Marucci L, Farneti A, Di Ridolfi P, Pinnaro P, Pellini R, Giannarelli D, Vici P, Conte M, Landoni V, **Sanguineti G**. Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer. *Head Neck.* 2017 May 31. doi: 10.1002/hed.24832. [Epub ahead of print]
 130. Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, **Sanguineti G**, Strigari L. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. *J Clin Oncol.* 2017 Jun 10;35(17):1891-1897. doi: 10.1200/JCO.2016.70.4189. Epub 2017 Mar 29.
 131. Pota M, Scalco E, **Sanguineti G**, Farneti A, Cattaneo GM, Rizzo G, Esposito M. Early prediction of radiotherapy-induced parotid shrinkage and toxicity based on CT radiomics and fuzzy classification. *Artif Intell Med.* 2017 Mar 18. pii: S0933-3657(17)30111-2. doi: 10.1016/j.artmed.2017.03.004.
 132. Vidiri A, Marzi S, Gangemi E, Benevolo M, Rollo F, Farneti A, Marucci L, Spasiano F, Sperati F, Di Giuliano F, Pellini R, Sanguineti G. Intravoxel incoherent motion diffusion-weighted imaging for oropharyngeal squamous cell carcinoma: Correlation with human papillomavirus Status. *Eur J Radiol.* 2019 Oct;119:108640. doi: 10.1016/j.ejrad.2019.08.009. Epub 2019 Aug 13.
 133. Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, **Sanguineti G**, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carboognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamaqi C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. *Int J Cancer.* 2019 Jul 22. doi: 10.1002/ijc.32583.
 134. Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, **Sanguineti G**, Soong YL, Tao Y, Yom SS, Wee JT. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2019 Nov 1;105(3):567-580. doi: 10.1016/j.ijrobp.2019.06.2540. Epub 2019 Jul 2.

135. Spriano G, Mercante G, Manciooco V, Cristalli G, **Sanguinetti G**, Ferrel F. A new lateral cervical approach for salvage total laryngo-pharyngectomy. *Acta Otorhinolaryngol Ital*. 2019 Feb;39(1):61–64. doi: 10.14639/0392-100X-1753.
136. Vahabi M, Pulito C, Sacconi A, Donzelli S, D'Andrea M, Manciooco V, Pellini R, Paci P, **Sanguinetti G**, Striqari L, Spriano G, Muti P, Pandolfi PP, Strano S, Safarian S, Ganci F, Blandino G. miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. *J Exp Clin Cancer Res*. 2019 Mar 29;38(1):141. doi: 10.1186/s13046-019-1119-x.
137. **Sanguinetti G**, Giannarelli D, Petronqari MG, Arcanqeli S, Sangiovanni A, Saracino B, Farneti A, Faiella A, Conte M, Arcanqeli G. Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study. *Radiat Oncol*. 2019 Jan 30;14(1):23. doi: 10.1186/s13014-019-1223-2.
138. Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, **Sanguinetti G**, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Serqi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamaqni C, Rubino D, Cortesi E, Maqri V, Pomati G, Scaqnoli S, Capomolla E, Kaval R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carboqnin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficarella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. *J Cell Physiol*. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.
139. Bossi P, Miceli R, Benasso M, Corvò R, Baciqualupo A, **Sanguinetti G**, Fallai C, Merlano MC, Infante G, Dani C, Di Giannantonio V, Licitra L. Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. *Head Neck*. 2018 Dec;40(12):2648-2656. doi: 10.1002/hed.25389. Epub 2018 Nov 17.
140. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Serqi D, Iezzi L, Mauqeri-Saccà M, Vaccaro A, Maqnolfi E, Gelibter A, Barchiesi G, Maqri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carboqnin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, **Sanguinetti G**, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. *Cancer Biol Ther*. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.
141. Marzi S, Farneti A, Vidiri A, Di Giuliano F, Marucci L, Spasiano F, Terrenato I, **Sanguinetti G**. Radiation-induced parotid changes in oropharyngeal cancer patients: the role of early functional imaging and patient-/treatment-related factors. *Radiat Oncol*. 2018 Oct 1;13(1):189. doi: 10.1186/s13014-018-1137-4.
142. Mandoj C, Pizzuti L, Serqi D, Sperduti I, Mazzotta M, Di Lauro L, Amodio A, Carpano S, Di Benedetto A, Botti C, Ferranti F, Antenucci A, D'Alessandro MG, Marchetti P, Tomao S, **Sanguinetti G**, Giordano A, Mauqeri-Saccà M, Ciliberto G, Conti L, Vici P, Barba M. Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. *J Transl Med*. 2018 May 16;16(1):129. doi: 10.1186/s12967-018-1511-x.
143. Iacorossi L, Di Ridolfi P, Biqiarini L, Giannarelli D, **Sanguinetti G**. [The impact of Reiki on side effects in patients with head-neck neoplasia undergoing radiotherapy: a pilot study]. *Prof Inferm*. 2017 Oct-Dec;70(3):214-221. doi: 10.7429/pi.2017.704214. Italian.
144. Pinnarò P, Giordano C, Farneti A, Faiella A, Iaccarino G, Landoni V, Giannarelli D, Vici P, Striqari L, **Sanguinetti G**. Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study. *J Exp Clin Cancer Res*. 2017 Dec 27;36(1):191. doi: 10.1186/s13046-017-0640-z.
145. Alterio D, Gerardi MA, Cella L, Spoto R, Zurlo V, Sabbatini A, Fodor C, D'Avino V, Conson M, Valoriani F, Ciardo D, Pacelli R, Ferrari A, Maisonneuve P, Preda L, Bruschini R, Cossu Rocca M, Rondi E, Colanqione S, Palma G, Dicuonzo S, Orecchia R, **Sanguinetti G**, Jereczek-Fossa BA. Radiation-induced acute dysphagia : Prospective observational study on 42 head and neck cancer patients. *Strahlenther Onkol*. 2017 Nov;193(11):971-981. doi: 10.1007/s00066-017-1206-x. Epub 2017 Sep 7.
146. Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, **Sanguinetti G**, Di Filippo S, di Lauro L, Serqi D, Catenaro T, Tomao S, Giordano A, Mauqeri-Saccà M, Barba M, Vici P. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. *Sci Rep*. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.
147. **G Sanguinetti**, R Corvò. Nasopharyngeal carcinoma: state of the art and new perspectives (review). *Oncol Rep* 1999 Mar-Apr;6(2):377-91
148. **G Sanguinetti**, P Bossi, A Pou, L Licitra. Timing of Chemoradiotherapy and Patient Selection for Locally Advanced Nasopharyngeal Carcinoma. *Clin Oncol (R Coll Radiol)*. 2003; 15(8): 451-60 (review).
149. Sosa M, **Sanguinetti G**. External beam radiotherapy as definitive treatment for prostate cancer. *Minerva Urol Nefrol*. 2003 Dec;55(4):263-275 (invited review)
150. C Fiorino, R Valdagni, T Rancati, **G. Sanguinetti**. DOSE-VOLUME EFFECTS FOR NORMAL TISSUES IN EXTERNAL RADIOTHERAPY: PELVIS. *Radiother Oncol*. 2009 Nov;93(2):153-67. (educational review)
151. Krasniqi E, Barba M, Venuti A, Pizzuti L, Cappuzzo F, Landi L, Carpano S, Marchetti P, Villa A, Vizza E, Giuliano G, Mazzotta M, Marinelli D, Gnignera S, Vincenzoni C, Stranges V, Serqi D, Giordano A, Tomao F, Mauqeri-Saccà M, Sanguinetti G, Di Lisa FS, Tomao S, Ciliberto G, Vici P. Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. *J Clin Med*. 2021 Apr 6;10(7):1525. doi: 10.3390/jcm10071525. PMID: 33917435 Free PMC article. Review.
152. Fiorino C, **Sanguinetti G**, Valdagni R. In response to Dr. G. Bauman and Dr. G. Rodrigues. *Int J Radiat Oncol Biol Phys*. 2004;59(3):914-5.

153. Fiorino C, **Sanguineti G**, Valdagni R. In regard to Brenner D J. "Fractionation and late rectal toxicity": no reliable estimates of ... value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels. *Int J Radiat Oncol Biol Phys*. 2005;62(1):289–90
154. A Eisbruch, J Harris, AS Garden, CKS Chao, W Straube, PM Harari, **G Sanguineti**, CU Jones, WR Bosch, KK Ang. Response to Letter by Dr. Ibott et al. *Int J Rad Oncol Biol Phys*, Volume 76, Issue 2, 1 February 2010, Page 639
155. Licitra L, Bonomo P, **Sanguineti G**, Baciqualupo A, Baldi GG, Valerini S, Bruzzi P. Different View on Larynx Preservation Evidence-Based Treatment Recommendations. *J Clin Oncol*. 2018 May 1;36(13):1376–1377. doi: 10.1200/JCO.2018.77.8001. Epub 2018 Mar 20. No abstract available.
156. Sanguineti G. Re: Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. *Radiother Oncol*, 2021. 157: p. 122–129. 19:S0167–8140(21)06249–6. doi: 10.1016/j.radonc.2021.05.011. Online ahead of print. PMID: 3402284
157. **Sanguineti G**, DeWeese T. Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done? *Oncology* (invited commentary)
158. **Sanguineti G**. Review of `Principles and Practice of Head and Neck Cancer Surgery and Oncology` by Montgomery, Rhys-Evans and Gullane, Informa, 2009 for the *Int J Radiat Oncol Biol Phys* (press)
159. Thariat J, Yom SS, Sanguineti G, Corry J. Oncology scan--nodal regions, nodal regression, and molecular biomarkers: new thinking in head and neck radiation therapy. *Int J Radiat Oncol Biol Phys*. 2014 Nov 1;90(3):477–9 (editorial)
160. **Sanguineti G**, Licitra L. How Much of the Future Can Be Read Through the Skin? *Int J Radiat Oncol Biol Phys*. 2016 Aug 1;95(5):1355–6. doi: 10.1016/j.ijrobp.2016.05.015. (editorial)
161. Culp L, Pou A, Jones D, Bayouth J, **Sanguineti G**. A Case of Radiation Recall Mucositis Associated with Docetaxel. *Head Neck*. 2004 Feb;26(2):197–200 (case report)
162. Gunn GB, Patel AJ, Gallegos J, Anderson KE, Hatch SS, **Sanguineti G**. Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a case report and literature review. *Head Neck* (in press)
163. Ingrosso G, Becherini C, Francolini G, Lancia A, Alì E, Caini S, Teriaca MA, Marchionni A, Filippi AR, Livi L, Sanguineti G, Aristei C, Detti B. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. *Crit Rev Oncol Hematol*. 2021 Mar;159:103242. doi: 10.1016/j.critrevonc.2021.103242. Epub 2021 Feb 2. PMID: 33545356 Review
164. Annovazzi A, Faiella A, Pescarmona E, Sanguineti G, Sciuto R. Asymptomatic Metastasis to Thyroid Cartilage Detected by 18F-Choline and 64Cu-PSMA PET/CT as a Single Site of Disease Relapse in a Patient With Castration-Resistant Prostate Carcinoma. *Clin Nucl Med*. 2020 Mar;45(3):214–216. doi: 10.1097/RLU.0000000000002786. PMID: 31652161
165. Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, Sanguineti G, Massimiani G, Sergi D, Carpano S, Marchetti P, Tomao S, Gamucci T, De Maria R, Tomao F, Natoli C, Tinari N, Ciliberto G, Barba M, Vici P. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. *J Hematol Oncol*. 2019 Oct 29;12(1):111. doi: 10.1186/s13045-019-0798-2. PMID: 31665051 Free PMC article. Review.
166. Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. *J Cancer*. 2019 Oct 12;10(24):5903–5914. doi: 10.7150/jca.35109. eCollection 2019. PMID: 31762800 Free PMC article. Review.
167. Bergamini C, Cavalieri S, Sanguineti G, Farneti A, Licitra L. Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. *Oxf Med Case Reports*. 2019 Oct 31;2019(10):omz102. doi: 10.1093/omcr/omz102. eCollection 2019 Oct. PMID: 31772741 Free PMC article.
168. Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moscetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. *J Cell Physiol*. 2020 Nov;235(11):7900–7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15. PMID: 31943171
169. Ganci F, Pulito C, Valsoni S, Sacconi A, Turco C, Vahabi M, Manciooco V, Mazza EMC, Meens J, Karamboulas C, Nichols AC, Covello R, Pellini R, Spriano G, Sanguineti G, Muti P, Bicciato S, Ailles L, Strano S, Fontemaggi G, Blandino G. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res*. 2020 Jun 15;26(12):2956–2971. doi: 10.1158/1078-0432.CCR-19-2485. Epub 2020 Jan 22. PMID: 31969334
170. Sanguineti G, Faiella A, Farneti A, D'Urso P, Fuga V, Olivieri M, Giannarelli D, Marzi S, Iaccarino G, Landoni V. Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions. *Clin Transl Radiat Oncol*. 2020 Jan 31;21:91–97. doi: 10.1016/j.ctro.2020.01.006. eCollection 2020 Mar. PMID: 32072030
171. Vidiri A, Gangemi E, Ruberto E, Pasqualoni R, Sciuto R, Sanguineti G, Farneti A, Benevolo M, Rollo F, Sperati F, Spasiano F, Pellini R, Marzi S. Correlation between histogram-based DCE-MRI parameters and 18F-FDG PET values in oropharyngeal squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes. *PLoS One*. 2020 Mar 2;15(3):e0229611. doi: 10.1371/journal.pone.0229611. eCollection 2020. PMID: 32119697
171. Sanguineti G, Bertini L, Faiella A, Ferriero MC, Marzi S, Farneti A, Landoni V. Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy. *Tumori*. 2021 Feb;107(1):55–63. doi: 10.1177/0300891620908950. Epub 2020 Mar 17. PMID: 32180511

172. Pizzuti L, Krasniqi E, Mandoj C, Marinelli D, Sergi D, Capomolla E, Paoletti G, Botti C, Kayal R, Ferranti FR, Sperduti I, Perracchio L, Sanguineti G, Marchetti P, Ciliberto G, Barchiesi G, Mazzotta M, Barba M, Conti L, Vici P. Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. *Cancers (Basel)*. 2020 Apr 1;12(4):849. doi: 10.3390/cancers12040849. PMID: 32244657
173. Pellini R, Zocchi J, Moretto S, Mazzola F, Bonsembiante A, Pichi B, Petruzzi G, De Virgilio A, Sanguineti G. Laryngeal vs oropharyngeal cancer: T2 or not T2. *Oral Oncol*. 2020 Oct;109:104678. doi: 10.1016/j.oraloncology.2020.104678. Epub 2020 Apr 7. PMID: 32273151 No abstract available.
174. Donzelli S, Farneti A, Marucci L, Ganci F, Sacconi A, Strano S, Sanguineti G, Blandino G. Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. *Front Cell Dev Biol*. 2020 Apr 21;8:257. doi: 10.3389/fcell.2020.00257. eCollection 2020. PMID: 32373612 Free PMC article. Review.
175. Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E, Sergi D, Amodio A, Natoli C, Gamucci T, Vizza E, Marchetti P, Botti C, Sanguineti G, Ciliberto G, Barba M, Vici P. Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. *Int J Mol Sci*. 2020 May 16;21(10):3528. doi: 10.3390/ijms21103528. PMID: 32429381 Free PMC article. Review.
176. Sanguineti G, Vidiri A, Pellini R. Is postoperative radiotherapy routinely indicated after total laryngectomy for pT3N0-1 supraglottic carcinoma? *Oral Oncol*. 2020 Aug;107:104825. doi: 10.1016/j.oraloncology.2020.104825. Epub 2020 May 31. PMID: 32487464 No abstract available.
177. De Felice F, Bonomo P, Sanguineti G, Orlandi E. Moderately accelerated intensity-modulated radiation therapy using simultaneous integrated boost: Practical reasons or evidence-based choice? A critical appraisal of literature. *Head Neck*. 2020 Nov;42(11):3405-3414. doi: 10.1002/hed.26400. Epub 2020 Aug 6. PMID: 32767530 Review.
178. Pellini R, Zocchi J, Pichi B, Mancio V, Marchesi P, Sperduti I, Mercante G, Molteni G, Iocca O, Di Maio P, De Virgilio A, Vidiri A, Sanguineti G, Spriano G. Prevention of fistulas after salvage laryngectomy using temporoparietal fascia free flap. *Acta Otorhinolaryngol Ital*. 2020 Jun;40(3):181-189. doi: 10.14639/0392-100X-N0411. PMID: 32773779
179. Alterio D, Volpe S, Bacigalupo A, Bonomo P, De Felice F, Dionisi F, D'Onofrio I, D'Angelo E, Di Rito A, Fanetti G, Franco P, Maddalo M, Merlotti A, Micciché F, Orlandi E, Paiar F, Ursino S, Pepa M, Corvò R, Di Muzio NG, Magrini SM, Russi E, Sanguineti G, Jereczek-Fossa BA, Donato V, Musio D. Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). *Med Oncol*. 2020 Aug 17;37(10):85. doi: 10.1007/s12032-020-01409-2. PMID: 32808089 Free PMC article.
180. Bresolin A, Garibaldi E, Faiella A, Cante D, Vavassori V, Waskiewicz JM, Girelli G, Avuzzi B, Villa E, Magli A, Noris Chiorda B, Munoz F, Sanguineti G, Gabriele P, Gatti M, Rancati T, Valdagni R, Di Muzio N, Fiorino C, Cozzarini C. Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. *Front Oncol*. 2020 Jul 23;10:1207. doi: 10.3389/fonc.2020.01207. eCollection 2020. PMID: 32850354 Free PMC article.
181. Pelle F, Cappelli S, Graziano F, Piarulli L, Cavicchi F, Magagnano D, De Luca A, De Vita R, Pozzi M, Costantini M, Varanese A, Panimolle M, Gullo PP, Barba M, Vici P, Vizza E, Cognetti F, Sanguineti G, Saracca E, Ciliberto G, Botti C. Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome. *J Exp Clin Cancer Res*. 2020 Aug 27;39(1):171. doi: 10.1186/s13046-020-01683-y. PMID: 32854728 Free PMC article.
182. Corvò R, Giaretti W, Sanguineti G, Geido E, Bacigalupo A, Franzone P, Mereu P, Garaventa G, Barbieri M, Vitale V. Ruolo prognostico dei parametri della cinetica cellulare nei tumori della testa e del collo trattati con radioterapia esclusiva [The prognostic role of the parameters of cellular kinetics in head and neck tumors treated solely by radiotherapy]. *Radiol Med*. 1993 Jul-Aug;86(1-2):135-42. Italian. PMID: 8346344.
183. Margarino G, Scala M, Schenone G, Mereu P, Corvo R, Sanguineti G, Giaretti W, Geido E, Orecchia R, Meszaros P, et al. Test di cinetica cellulare e pianificazione dei trattamenti dei tumori epidermoidali del capo e del collo [Cell kinetic analysis and treatment planning in epidermoid tumors of the head and neck]. *Acta Otorhinolaryngol Ital*. 1992 Sep-Oct;12(5):421-33. Italian. PMID: 1303006.
184. Guenzi M, Sanguineti G, Botto F, Ghiso G, Andreucci L, Vitale V. Una proposta tecnica per il trattamento della mammella e dei linfonodi regionali in pazienti affette da neoplasia operate conservativamente [A proposal for the treatment technique for the breast and regional lymph nodes in patients with conservatively operated neoplasms]. *Radiol Med*. 1990 Oct;80(4 Suppl 1):77-80. Italian. PMID: 2251423.
185. Guenzi M, Scarpati D, Corvò R, Sanguineti G, Gardin G, Conte PF, Vitale V. Ruolo della radioterapia nel trattamento multimodale del carcinoma mammario localmente avanzato [The role of radiotherapy in the multimodal treatment of locally advanced breast carcinoma]. *Radiol Med*. 1990 May;79(5):534-8. Italian. PMID: 2359862.
186. Corvò R, Scarpati D, Sanguineti G, Vitale V. La predittività della risposta radioterapica nei tumori epidermoidi della testa e del collo. Revisione della letteratura e modelli matematici per la scelta dei frazionamenti [The predictability of the radiotherapy response in epidermoid tumors of the head and neck. A review of the literature and mathematical models for choosing the fractionated doses]. *Radiol Med*. 1990 May;79(5):520-9. Italian. PMID: 2193325.
187. Sanguineti G, Corvò R, Frascio F, Vitale V. Radioterapia accelerata con la tecnica del supplemento di dose concomitante in pazienti affetti da carcinoma squamoso della testa e del collo [Accelerated radiotherapy with the concomitant-boost technic in patients with squamous cell carcinoma of the head and neck]. *Radiol Med*. 1994 Nov;88(5):650-6. Italian. PMID: 7824783.
188. Marinelli D, Mazzotta M, Pizzuti L, Krasniqi E, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Sperduti I, Sanguineti G, Botticelli A, Fabbri A, Botti C, Ciliberto G, Barba M, Vici P. Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. *Cancers (Basel)*. 2020 Sep 3;12(9):2497. doi: 10.3390/cancers12092497. PMID: 32899209 Free PMC article.

189. Sacconi A, Donzelli S, Pulito C, Ferrero S, Spinella F, Morrone A, Rigoni M, Pimpinelli F, Ensoli F, Sanguineti G, Pellini R, Agrawal N, Izumchenko E, Ciliberto G, Gianni A, Muti P, Strano S, Blandino G. TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. *J Exp Clin Cancer Res.* 2020 Sep 23;39(1):200. doi: 10.1186/s13046-020-01708-6. PMID: 32967703 Free PMC article.
190. Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le QT, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtneess BA, Ghi MG, Sanguineti G, O'Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon JP, Mell LK; MARCH/MACH-NC Collaborative Group and the Head and Neck Cancer Intergroup. Predictive classifier for intensive treatment of head and neck cancer. *Cancer.* 2020 Dec 15;126(24):5263-5273. doi: 10.1002/cncr.33212. Epub 2020 Oct 5. PMID: 33017867
191. Ganci F, Allegretti M, Manciocco V, Fiorentino F, Sanguineti G, Giacomini P, Pellini R, Spinella F, Blandino G. Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood. *Oral Oncol.* 2021 Apr;115:105096. doi: 10.1016/j.oraloncology.2020.105096. Epub 2020 Nov 21. PMID: 33234482 No abstract available.
192. Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. *J Exp Clin Cancer Res.* 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3. PMID: 33302999
193. Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtneess B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazon JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Ruo Redda MG, Racadot S, Fountzilias G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. *Radiother Oncol.* 2021 Mar;156:281-293. doi: 10.1016/j.radonc.2021.01.013. Epub 2021 Jan 27. PMID: 33515668
194. Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HCW, Corry J, Grégoire V, Harrington KJ, Hu CS, Jensen K, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Pan JJ, Peters LJ, Poh SS, Rosenthal DI, Sanguineti G, Tao Y, Wee JT, Yom SS, Chua MLK, Lee AWM. International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2021 Jul 1;110(3):682-695. doi: 10.1016/j.ijrobp.2021.01.041. Epub 2021 Feb 9. PMID: 33571626 Review.
195. Detti B, Ingrosso G, Becherini C, Lancia A, Olmetto E, Ali E, Marani S, Teriaca MA, Francolini G, Sardaro A, Aristei C, Filippi AR, Sanguineti G, Livi L. Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change. *Cancer Treat Res Commun.* 2021;27:100331. doi: 10.1016/j.ctarc.2021.100331. Epub 2021 Feb 6. PMID: 33581491 Free PMC article. Review.
196. Bresolin A, Faiella A, Garibaldi E, Munoz F, Cante D, Vavassori V, Waskiewicz JM, Girelli G, Avuzzi B, Villa E, Magli A, Noris Chiorda B, Gatti M, Ferella L, Maggio A, Landoni V, Aimonetto S, Sini C, Rancati T, Sanguineti G, Valdagni R, Di Muzio N, Fiorino C, Cozzarini C. Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. *Radiother Oncol.* 2021 May;158:74-82. doi: 10.1016/j.radonc.2021.02.026. Epub 2021 Feb 25. PMID: 33639190
197. Magli A, Farneti A, Faiella A, Ferriero M, Landoni V, Giannarelli D, Moretti E, de Paula U, Gomellini S, Sanguineti G. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2021 Sep 1;111(1):93-100. doi: 10.1016/j.ijrobp.2021.03.027. Epub 2021 Mar 19. PMID: 33745951.
198. Sanguineti G, Pellini R, Vidiri A, Marzi S, D'Urso P, Terrenato I, Farneti A, Fuga V, Ungania S, Landoni V. Stereotactic body radiotherapy for T1 glottic cancer: dosimetric data in 27 consecutive patients. *Tumori.* 2021 Apr 6;3008916211000440. doi: 10.1177/03008916211000440. Online ahead of print. PMID: 33821713
199. Giovanetti A, Marconi R, Awad N, Abuzied H, Agamy N, Barakat M, Bartoleschi C, Bossi G, Canfora M, Elsaid AA, Ioannilli L, Ismail HM, Issa YA, Novelli F, Pardini MC, Pioli C, Pinnarò P, Sanguineti G, Tahoun MM, Turchi R, Strigari L. Validation of a biomarker tool capable of measuring the absorbed dose soon after exposure to ionizing radiation. *Sci Rep.* 2021 Apr 14;11(1):8118. doi: 10.1038/s41598-021-87173-3. PMID: 33854097 Free PMC article.
200. Krasniqi E, Pizzuti L, Valerio MR, Capomolla E, Botti C, Sanguineti G, Marchetti P, Anselmi E, Tomao S, Giordano A, Ficorella C, Cannita K, Livi L, Meattini I, Mauri M, Greco F, Veltri EM, Michelotti A, Moscetti L, Giotta F, Lorusso V, Paris I, Tomao F, Santini D, Tonini G, Villa A, Gebbia V, Gamucci T, Ciliberto G, Sperduti I, Mazzotta M, Barba M, Vici P. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. *Int J Med Sci.* 2021 Mar 27;18(10):2245-2250. doi: 10.7150/ijms.54996. eCollection 2021. PMID: 33859534 Free PMC article.
201. Petit C, Lacas B, Pignon JP, Le QT, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar MKB, Lee JW, Ghi MG, Sanguineti G, Temam S, Cheungoua-Zanetsie M, O'Sullivan B, Posner MR, Vokes EE, Cruz Hernandez JJ, Szutkowski Z, Lartigau E, Budach V, Suwiński R, Poulsen M, Kumar S, Ghosh Laskar S, Mazon JJ, Jeremic B, Simes J, Zhong LP, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P; MACH-NC and MARCH Collaborative Groups. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. *Lancet Oncol.* 2021 May;22(5):727-736. doi: 10.1016/S1470-2045(21)00076-0. Epub 2021 Apr 13. PMID: 33862002
202. Perillo A, Landoni V, Farneti A, Sanguineti G. Organ motion in linac-based SBRT for glottic cancer. *Radiat Oncol.* 2021 Jun 12;16(1):106. doi: 10.1186/s13014-021-01833-2. PMID: 34118965
203. Rancati T, Fiorino C, Sanguineti G, Valdagni R, Orlandi E. Editorial: Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic Ratio in the Modern Radiation Therapy Era. *Front Oncol.* 2021 May 26;11:690649. doi: 10.3389/fonc.2021.690649. eCollection 2021.

204. Alterio D, D'Urso P, Volpe S, Tagliabue M, De Berardinis R, Augugliaro M, Gandini S, Maffini FA, Bruschini R, Turturici I, Riccio S, Calabrese L, Farneti A, Starzyńska A, Ferrari A, Jereczek-Fossa BA, Ansarin M, Sanguineti G. The Impact of Post-Operative Radiotherapy in Early Stage (pT1–pT2N0M0) Oral Tongue Squamous Cell Carcinoma in Era of DOI. *Cancers (Basel)*. 2021 Sep 28;13(19):4851. doi: 10.3390/cancers13194851. PMID: 34638335; PMCID: PMC8507768.
205. Piludu F, Marzi S, Gangemi E, Farneti A, Marucci L, Venuti A, Benevolo M, Pichi B, Pellini R, Sperati F, Covello R, Sanguineti G, Vidiri A. Multiparametric MRI Evaluation of Oropharyngeal Squamous Cell Carcinoma. A Mono-Institutional Study. *J Clin Med*. 2021 Aug 28;10(17):3865. doi: 10.3390/jcm10173865. PMID: 34501313; PMCID: PMC8432241.
206. Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, Cappuzzo F, Landi L, Sergi D, Pelle F, Cappelli S, Botti C, Vizza E, Tomao S, Marchetti L, Sanguineti G, Botticelli A, Marchetti P, Magri V, Pisegna S, Venuti A, Tomao F, Buzzacchino F, Ciliberto G, Barba M, Vici P. Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care? *Cancers (Basel)*. 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061. PMID: 34439215; PMCID: PMC8391130.
207. Dionisi F, Widesott L, Van Vulpen M, Fuller CD, Frondizi R, Meneguzzo M, Blanchard P, Amichetti M, Sanguineti G. Methodologies to Increase the Level of Evidence of Real-life Proton Therapy in Head and Neck Tumors. *Int J Part Ther*. 2021 Jun 25;8(1):328–338. doi: 10.14338/IJPT-20-00051.1. PMID: 34285959; PMCID: PMC8270108.
208. Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daralioi T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. *Sci Rep*. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z. PMID: 34215766; PMCID: PMC8253801.
209. Munoz F, Sanguineti G, Bresolin A, Cante D, Vavassori V, Waskiewicz JM, Girelli G, Avuzzi B, Garibaldi E, Faiella A, Villa E, Magli A, Noris Chiorda B, Gatti M, Rancati T, Valdagni R, Di Muzio NG, Fiorino C, Cozzarini C. Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. *Cancers (Basel)*. 2021 Jun 29;13(13):3243. doi: 10.3390/cancers13133243. PMID: 34209562; PMCID: PMC8269132.
210. Sanguineti G. Re: Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. *Radiother Oncol*, 2021. 157: p. 122–129. *Radiother Oncol*. 2021 Aug;161:251–252. doi: 10.1016/j.radonc.2021.05.011. Epub 2021 May 19. PMID: 34022284.
211. Marzi S, Farneti A, Marucci L, D'Urso P, Vidiri A, Gangemi E, Sanguineti G. The Role of Patient- and Treatment-Related Factors and Early Functional Imaging in Late Radiation-Induced Xerostomia in Oropharyngeal Cancer Patients. *Cancers (Basel)*. 2021 Dec 15;13(24):6296. doi: 10.3390/cancers13246296.
212. Masi M, Landoni V, Faiella A, Farneti A, Marzi S, Guerrisi M, Sanguineti G. Comparison of rigid and deformable coregistration between mpMRI and CT images in radiotherapy of prostate bed cancer recurrence. *Phys Med*. 2021 Nov 27;92:32–39. doi: 10.1016/j.ejmp.2021.11.010.
213. Faiella A, Sciuto R, Giannarelli D, Bottero M, Farneti A, Bertini L, Rea S, Landoni V, Vici P, Ferriero MC, Sanguineti G. A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either ⁶⁴CuCl₂ or ⁶⁴CuPSMA PET/CT. *Cancers (Basel)*. 2021 Nov 6;13(21):5564. doi: 10.3390/cancers13215564.
214. Alterio D, De Berardinis R, Augugliaro M, D'Urso P, Volpe S, Maffini F, Bruschini R, Marvaso G, Riccio S, Tagliabue M, Turturici I, Farneti A, Calabrese L, Starzyńska A, Ferrari A, Zaffaroni M, Jereczek-Fossa BA, Sanguineti G, Ansarin M. Indication to postoperative radiotherapy for oral cavity squamous cell carcinoma: what's new in the Depth of Infiltration (DOI) era? *Br J Radiol*. 2021 Dec 17:20210705. doi: 10.1259/bjr.20210705.

Capitoli di libri

1. `Oropharynx` in *Radiation Oncology: A question-based review*, Hristov, Lin and Christodouleas (eds), Lippincott Williams & Wilkins 2010
2. `Nasopharynx` in *Radiation Oncology: A question-based review*, Hristov, Lin and Christodouleas (eds), Lippincott Williams & Wilkins 2010
3. `Unknown primary cancer` in *Radiation Oncology: A question-based review*, Hristov, Lin and Christodouleas (eds), Lippincott Williams & Wilkins 2010
4. 'Salivary gland tumors: Radiotherapy' in *Salivary Gland Cancer: From diagnosis to tailored treatment*, Lisa Licitra and Laura Locati (eds), Springer 2019
5. 'Head and Neck: Larynx and Structures Involved in Swallowing/Nutritional Problems and Dysphonia' in *Modelling Radiotherapy side effects*, Claudio Fiorino and Tiziana Rancati (eds), CRC Press 2019
6. 'Locally intermediate supraglottic cancer: Radiotherapy' in *Laryngeal Cancer, Clinical Case-based approaches*, Dedivitis Rogério, Peretti Giorgio and Hanna Ehab (eds), Thieme 2019.

Extramural sponsorship

1992–96 Consiglio Nazionale Ricerche–Applicazioni Cliniche della Ricerca Oncologica (National Council of Research), Rome, Italy, CNR #96.00687.PF39 for the clinical research `Alternating Chemoradiotherapy versus concomitant boost radiotherapy for advanced head and neck cancer`. Total amount Lira 200.000.000 (about \$ 100,000).

2016–19 Associazione Italiana Ricerca sul Cancro, Milan, Italy, IG 2015 Id.1702896 for the clinical research `Early Diffusion Weighted Magnetic Resonance Imaging Changes to Predict Tumor Response to Chemoradiotherapy in HN Cancer`. Total amount Euro 255,000.

2019–2020 Astrazeneca grant to support Phase I–II study on durvalumab–SBRT before surgery in locally advanced HNSCC. Total amount Euro 140,000.

2019–23 Associazione Italiana Ricerca sul Cancro, Milan, Italy, IG 2019 Id. 23187 for the clinical research `A prospective randomized phase II trial of DCE–MRI hypoxia–targeted boost chemoradiotherapy for head and neck cancer`. Total amount Euro 525.226,02.

2021 Fondazione Memmo, research fund for the development of an application to manage patient schedules and outcomes. Total amount Euro 50,000.

Relazioni ad invito

Italy

1. "Trattamento multidisciplinare delle metastasi ossee vertebrali: linee guida. Indicazioni e risultati della radioterapia nelle localizzazioni vertebrali"(Multidisciplinary treatment of vertebral bone metastases: indications and results) June 17, 1993, Siena (Italy)
2. "La radioterapia nella palliazione"(Radiotherapy in palliation). Corso di formazione per assistenti domiciliari. April 18, 1994, Genova (Italy)
3. "La radioterapia nella palliazione" (Radiotherapy in palliation). Corso di formazione per assistenti domiciliari. June 10, 1996, Genova (Italy)
4. "Radioterapia dei tumori della testa e collo" (Radiotherapy of HN–SCC), Nov 14, 1995, Parma (Italy)
5. "La radioterapia nella palliazione"(Radiotherapy in palliation). Corso di formazione per assistenti domiciliari. June 13, 1997, Genova (Italy)
6. "Randomized studies of combined modality treatments in advanced head and neck cancer" An interdisciplinary approach to clinical oncology. New England Cancer Society meeting, May 13, 1997, S. Margherita Ligure (Genoa), Italy
7. "Postoperative radiotherapy after conservative surgery". Genoa, June 21, 2000
8. "Standard and advanced techniques in HNSCC". AIRO teaching course, Genoa, Italy, May 4, 2001
9. "Standard and advanced techniques in HNSCC". AIRO teaching course, Messina, Italy, May 26, 2001
10. "Tongue carcinoma: adjuvant treatments after surgery" Annual Meeting of the Italian Society of Maxillo–Facial Surgery, Naples, Italy, June 7, 2001
11. "Discussion" `How to write a scientific paper`, course, Genova, Italy, April 12, 2002
12. "Radiotherapy technique" `How to write a scientific paper`, Genova, Italy, April 11, 2002
13. "IMRT @ UTMB` National Cancer Institute, Milano, March 22, 2004 (seminario)
14. "IMRT @ UTMB` National Institute for Cancer Research, Genova, March 23, 2004 (seminario)
15. "From the clinical based to the biology guided therapy" Therapeutic news in the treatment of localized prostate cancer, Genova, September 15, 2004
16. "Volumes and fractionation" Therapeutic news in the treatment of localized prostate cancer, Genova, September 15, 2004
17. "Prostate Cancer: Radiation Therapy in Combination with Hormonal Therapy". Workshop, XIV AIRO meeting, Turin October 20, 2004
18. " Treatment of the N0 neck" Meeting of the SICMF (Italian Association of Head and Neck Surgery), Parma, Italy, June 11, 2005
19. "Clinical introduction to IGRT" AIRO meeting on prostate cancer, Milan, March 16, 2006
20. "The role of postoperative radiotherapy" Consensus conference on the treatment of laryngeal carcinoma, Milan, October 12, 2006
21. "Radiotherapy alone or in combination for high risk prostate cancer". Workshop, XVIII Meeting of the Italian Urologic Society, Pescara, Nov 27, 2008
22. "Altered fractionation and toxicity". Predictive Models of the Effects of External Beam Radiotherapy. Florence, November 24, 2010 (corso)
23. "Anatomic modifications to measure and predict toxicity in radiation oncology". Predictive Models of the Effects of External Beam Radiotherapy. Florence, November 26, 2010 (corso)
24. "Low and Intermediate risk prostate carcinoma. SIURO meeting, Radiotherapy, indications and limits". Naples, June 24, 2011 (corso)

25. "Aspetti metodologici - Nuovi endpoints & Livelli di evidenza" AIOM - AIRO LOMBARDIA 2011: LA MULTIDISCIPLINARIETA' NELL'ERA DELLE TARGETED THERAPIES E DELLA RADIOTERAPIA AD INTENSITA' MODULATA - MILANO, 14 OTTOBRE 2011 (Tavola Rotonda)
26. "IMRT per tumori dell'orofaringe". Istituto Europeo di Oncologia, 9/11/2011 (seminario)
27. "Impiego clinico VMAT: review". Tecniche Modulate di radioterapia esterna: Esperienze a confronto nel Triveneto. Udine, 4 ottobre 2013
28. "Ruolo della radioterapia radicale". Algoritmo terapeutico del carcinoma prostatico ad alto rischio, CORSO XXII CONGRESSO NAZIONALE SIURo, Bologna, 15 giugno 2012
29. "Ruolo della radioterapia radicale". WORKUP diagnostico e terapeutico nel CaP localmente avanzato, CORSO XXIII CONGRESSO NAZIONALE SIURo, Firenze, 12 giugno 2013
30. "Neoplasie del distretto cervico-cefalico". Simposi di Oncologia Integrata, Auditorium Villa Elios (Humanitas Gavazzeni), Bergamo, 17 Maggio 2012
31. "Il ruolo dell'Imaging nella preparazione del trattamento". La pianificazione del trattamento radiante, Trento, 29 Maggio 2012 (seminario)
32. "Il ruolo della Radioterapia nel trattamento integrato multimodale dei carcinomi dell'orofaringe alla luce delle innovazioni tecnologiche e delle più recenti acquisizioni biologiche". Varese 20 settembre 2012 (seminario)
33. "Set up errors e organ motion in Radioterapia per Tumori della Prostata". RADIOTERAPIA STEREOTASSICA BODY (SBRT) E TRATTAMENTI IPOFRAZIONATI CON LINAC (VMAT/RAPIDARC) E CON MACCHINE DEDICATE: ESPERIENZE A CONFRONTO" Varese, 29 Novembre 2012
34. "Ruolo della radioterapia", SCLC update, XII Congresso Nazionale FONICAP, Verona, 30 Nov 2012
35. "Therapeutic options in recurrent disease". 14 th Course: Advances in Urological Oncology "Prostate Cancer: from Molecular and Cellular Biology to Therapeutic Advancement" Erice, Sicily, Italy, April 16-21, 2013
36. "Importanza del contouring nell'outcome clinico". Corso AIRO: IMPOSTAZIONE RADIOTERAPICA NEI TUMORI DEL RINOFARINGE, Roma, 27 maggio 2013
37. "La de-intensificazione della Radioterapia" Il trattamento del Cancro Orofaringeo nell'era dell'HPV e della TORS, 100 Congresso della Società Italiana di Otorinolaringoiatria, Roma, 30 Maggio 2013
38. "Tossicità e frazionamenti alterati". Corso Modelli predittivi degli effetti della radioterapia con fasci esterni (2° edizione), Catania, 6 giugno 2013
39. "Modificazioni anatomiche per predire e misurare le tossicità in radioterapia ed implicazioni in ART. Corso Modelli predittivi degli effetti della radioterapia con fasci esterni (2° edizione), Catania, 6 giugno 2013
40. "Il trattamento della malattia oligometastatica". XV Congresso nazionale AIOM, Milano, 12 Ottobre, 2013
41. "la Radioterapia per tumori orofaringe". Poliambulanza, Brescia, 22 Nov 2013
42. "La malattia localmente avanzata: la Radioterapia". ASCO-ECCO per il testa-collo. Firenze, 23 Novembre 2013
43. "Il Razionale clinico". Adaptive radiotherapy tra tecnologia e clinica. Padova 9 Dicembre 2013
44. "Gli studi clinici. Come devono essere strutturati per ottenere risultati corretti.". I Giovedì in Radioterapia IV Ed, Istituto Nazionale Tumori, Fondazione Pascale, Napoli, 23 Genn 2014
45. "Ruolo della Radioterapia nella bladder preservation". Conferenza SIURO Interregionale - Il carcinoma della vescica: uno sguardo a 360 gradi. Meldola (FO) 28 Marzo 2014
46. "La radioterapia Basata sull'evidenza" Radioterapia e chirurgia basate sull'evidenza nel carcinoma prostatico ad alto rischio. Aula didattica torre 7 piano terra, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, 27 Marzo 2014
47. "Terapia chirurgica vs terapia radiante vs terapie combinate". Siuro Winter School, Firenze 13 febbraio 2015
48. "Terapia adiuvante/terapia di salvataggio". Siuro Winter School, Firenze 13 febbraio 2015
49. "Expert Under Fire "Il radioterapista incontra l'Urologo, l'Oncologo Medico e il Metodologo" XXV CONGRESSO NAZIONALE SIURo, Roma, 23 Giugno 2015
50. "Tumore della prostata: Il trattamento delle recidive cliniche locali e loco-regionali dopo trattamento radicale. Ruolo della RT nel trattamento della recidiva clinica." XXV CONGRESSO NAZIONALE SIURo, Roma, 22 Giugno 2015
51. "Debate II: Postoperative radiotherapy. Contrast". A new age in the management of mCRPC patients -Works in progress. Trento, 12 giugno 2014
52. "Ruolo della Radioterapia radicale. Work up diagnostico e terapeutico nel Ca prostatico a rischio alto e molto alto (T3-4 e/o N1)." XXIV CONGRESSO NAZIONALE SIURo, BOLOGNA 22 Giugno 2014
53. "Possibilità terapeutiche. Radioterapia. Carcinoma prostatico a rischio molto basso." XXIV CONGRESSO NAZIONALE SIURo, BOLOGNA 24 Giugno 2014
54. "My preferred P&K abstracts at ESTRO and/or ASTRO meetings 2015". 4th World Top Communications of the year in Genitourinary Oncology. Arezzo, October 8, 2015
55. High-risk tumor management. 16th Course: "ADVANCES IN UROLOGICAL ONCOLOGY". Erice, April 16th, 2015
56. INNOVAZIONI STRATEGICHE NEL TRATTAMENTO DEI TUMORI DELLA PROSTATA. Innovazione clinico-tecnologica nel trattamento multimodale dei tumori della prostata Roma 26 marzo 2015
57. "Moderne tecniche radioterapiche per preservare la funzione: MRT e nuove prospettive tecnologiche". 4° Congresso Nazionale AIOCC. Update 2014 in Oncologia Cervico-cefalica. Genova, 21 Novembre 2014
58. "La malattia localmente avanzata. Radioterapia". ASCO-ECCO 2013 per il testa-collo. Firenze, 23 Novembre 2014
59. Ruolo della Radioterapia nei tumori dell'orofaringe. 102° congresso SIO, Roma, 28 Maggio 2015 (lecture)
60. "Diagnosi, stadiazione, indicazione terapeutica e trattamento dei tumori laringei" 102° congresso SIO, Roma, 28 Maggio 2015 (lunch with the professor)
61. "Preservazione d'organo nel tumore vescicale infiltrante". Hot topics in urologia oncologica 2015. Bergamo, 9 Maggio 2015
62. "Bladder Sparing, update terapie integrate". Carcinoma uroteliale a cellule transizionali. Torino, 20 Marzo 2015
63. "Corso monotematico di aggiornamento nel cancro della laringe". 5° Congresso Nazionale AIOCC, 2 Marzo 2015, Roma

64. "Novità in radioterapia". Le neoplasie della laringe. Lucca 29 Marzo 2014
65. "Le innovazioni nella Radioterapia". Campagna PanCrea. Creiamo informazione. Un anno dopo. Roma, 13 Novembre 2014
66. "Volumi clinici nella radioterapia dei tumori del distretto cervico-cefalico". Congresso annuale della Associazione Italiana Radioterapia Oncologica (AIRO), Rimini 8 Novembre 2015 (Lezione di aggiornamento)
67. "Volume bersaglio e riduzione delle dosi: una prospettiva realizzabile?" Seminar on Nasopharyngeal Cancer, Milano 12 Novembre 2015
68. "Radioterapia per tumori dell'orofaringe e del cavo orale". Università di Napoli Federico II, Napoli, 19 Novembre 2015
69. "La radiochemioterapia nel trattamento delle forme benigne e maligne delle ghiandole salivari". 2nd winter course, Roccaraso (AQ), 26 Gennaio 2016
70. "Razionale ed utilizzo dello space OAR nel trattamento stereotassico del carcinoma prostatico", Bologna, 4 Marzo 2016
71. "Consensus Conference sulla Global Care del Paziente con Tumore Testa-Collo Ricorrente/Metastatico". Ist. Naz. Tumori, Milano, 5 maggio 2016
72. "La rivoluzione del Gleason Score con la nuova classificazione ISUP/WHO". XXIII Congresso Nazionale AURO, Roma, 23 Maggio 2016 (Panelist)
73. "Approccio multimodale e multidisciplinare al CRPC: chi tratta chi?" XXIII Congresso Nazionale AURO, Roma, 23 Maggio 2016 (Panelist)
74. "Quale opzione radioterapica nella malattia oligometastatica (SBRT vs WFRT)". XXVI Congresso Nazionale SIUR, Palazzo dei Congressi, Firenze 10 Giugno 2016 (panelist)
75. "Update on Gleason Score". Seminario Dipartimentale, Istituto Regina Elena, 18 Ottobre 2016
76. "Analisi dei contorni e parere dell'esperto". Corso teorico pratico. IL CONTOURING DELLE METASTASI LINFONODALI DEL COLLO A SEDE PRIMITIVA IGNOTA. Naples, May 31, 2016
77. "Management of advanced laryngeal cancer". 11th Congress of the European Laryngological Society, Genoa, June 9, 2016
78. "trattamenti e ritrattamenti radianti". Management della recidiva biochimica dopo trattamenti locali nel paziente M0. Rome, Nov 11, 2016
79. "Cosa cambia nella pratica clinica?". 2016 AIOM Best of the year, Rome, Nov 16, 2016
80. "Imaging durante e dopo il trattamento per predire la risposta" Modelli predittivi degli effetti della radioterapia con fasci esterni, Milan Nov 22, 2016
81. "Modelli dose-volume per i tessuti sani: testa-collo" Modelli predittivi degli effetti della radioterapia con fasci esterni, Milan Nov 23, 2016
82. "Ipo-frazionamento : cosa dice la radiobiologia". Dalla teoria alla pratica. La gestione del carcinoma prostatico in radioterapia. Metodiche, tecniche e strategie. Napoli 29 Novembre 2016
83. "Dosi e frazionamenti con tecniche ad intensità modulata: cosa è cambiato dalla radioterapia conformazionale?". Tumori dei seni paranasali e della base cranica, Milan Dec 12, 2016
84. "De-intensificazione terapeutica nel cancro orofaringeo HPV correlato: a che punto siamo?". 10 anno di vaccinazione HPV. Rome, March 25, 2017
85. "Ipo-frazionamenti e radiobiologia della mammella". Neoplasia della mammella: un unico problema, molteplici soluzioni, Macerata, April 7, 2017
86. "Il carcinoma prostatico a basso rischio". XXVII Congresso Nazionale SIURO, Napoli 20 Aprile 2017
87. "Il ProtecT da un punto di vista della Radioterapia". XXVII Congresso Nazionale SIURO, Napoli 20 Aprile 2017
88. "Il carcinoma prostatico oligometastatico alla diagnosi. Radioterapia: palliazione o cura?". XXVII Congresso Nazionale SIURO, Napoli 20 Aprile 2017
89. "Sorveglianza, chirurgia robotica e moderne tecniche di radioterapia: il candidato ideale". L'oncologo incontra il patologo, Arezzo, 17 Maggio 2017
90. "Lo studio ProtecT: Luci ed ombre". XXIV Congresso Nazionale AURO, Pisa May 20, 2017
91. "Carcinoma dell'orofaringe" 104° Congresso SIO, Sorrento May 26, 2017
92. "Ruolo della radioterapia nella malattia organo-confinata". Ruolo della Radioterapia nell'approccio multidisciplinare del carcinoma prostatico avanzato, Genova June 12, 2017
93. "Adaptive Radiation Therapy: when, how?" Tecniche 4D e adaptive radiation therapy: il "dominio del tempo" in radioterapia. Verona, June 13, 2017
94. "Ruolo della radioterapia nel cancro del cavo orale". SICMF 2017, June 16, 2017
95. "Tumore della Prostata rischio basso/intermedio" 5° Simposio Annuale UPMC Radioterapia Stereotassica - Esperienze del territorio a confronto Rome Oct 12, 2017
96. Metodiche e tecnologie a confronto: IMRT e adroterapia". Incontro multidisciplinare sulla patologia delle ghiandole salivari maggiori e minori, San Giovanni Rotondo (FG) Oct 20, 2017
97. "Idrogel Space-OAR: nuovi orizzonti in SBRT per la prostata". AIROut Experience. Rimini, Nov 11, 2017
98. "Ruolo della Radioterapia nelle metastasi ossee". Congresso Regionale OTDI Umbria, Le lesioni ripetitive dello scheletro, Foligno (PG) Nov 11, 2017
99. "Nuove tecnologie in Uro-oncologia". XXVIII Congresso Nazionale della Società Italiana di Urologia Oncologica, Milano 14 Aprile 2018
100. "Il frazionamento moderato". XXVIII Congresso Nazionale della Società Italiana di Urologia Oncologica, Milano 13 Aprile 2018
101. "Molecular Imaging and Unmet need in Prostate Cancer". XXVIII Congresso Nazionale della Società Italiana di Urologia Oncologica, Milano 13 Aprile 2018
102. "Adaptive radiotherapy nei tumori capo e collo". Co-registrazione di immagini deformabile in radioterapia: metodi, assicurazione di qualità ed applicazioni cliniche, corso AIFM, Naples June 14, 2018

103. "Il futuro della Radioterapia". Nuovi orizzonti in oncologia cervico-cefalica, giornata di studio AIOCC, Modena, Oct 4, 2018
104. "La ricerca clinica con le nuove tecnologie". XXVIII Congresso Nazionale AIRO, Rimini, 4 Nov 2018
105. "TUMORE DELLA PROSTATA E RECIDIVE PROSTATICHE E LINFONODALI". 6th Simposio Annuale UPMC, Rome Dec 15, 2018
106. "Il ruolo del radioterapista". Ottimizzazione dei percorsi diagnostico/terapeutici nel III stadio NSCLC. Roma, 11 Luglio 2019
107. "Immunomodulazione Radio-indotta". L'immunoterapia nei trattamenti multidisciplinari dei tumori del rene, del testa e collo e della vescica, Roma 26 Gennaio 2019
108. "Radiation Therapy. Novel indications and new strategies." Novel Clinical Strategies in NSCLC. Rome, May 9, 2019
109. "I casi che ci hanno messo in difficoltà: come il radiologo può aiutare l'oncologo e viceversa. I Tumori testa e collo.". Corso residenziale Difficoltà ed errori nella gestione dei pazienti oncologici. Come possono essere affrontati grazie all'intesa tra oncologo e radiologo, Roma, 22 marzo 2019
110. "Il carcinoma della prostata". Corso residenziale, Il Carcinoma della prostata: algoritmi terapeutici. Lido di Camaiore, 23 Febbraio, 2019
111. "La malattia prostatica oligometastatica: i dati e le ipotesi". Neoplasie avanzate del rene e della prostata, Narni (Terni) May 22, 2019
112. "Requisiti Tecnologici, Tecniche Radioterapiche e Constraints di dose nei trattamenti RT con ipofrazionamento spinto". Corso AIRO-LAM. I Tumori della prostata: pratica clinica e problemi aperti. L'aquila, April 18, 2019
124. "Le scelte del team multidisciplinare per il trattamento ottimale dei pazienti ". Special CARE 2019, Bologna May 17, 2019
125. "Tumori vescicali avanzati: le nuove prospettive dell'immunoterapia". XXVI Congresso Nazionale AURO, Bologna, May 18, 2019
126. "Moderni orientamenti nella radioterapia dei tumori delle ghiandole salivari" XXI Congresso Nazionale SICFM, Lecce 13 Giugno 2019
127. "Managing oligometastatic mRCC cases: the place for focal radiotherapy " World Top Communications of the Year in Genito-Urinary Oncology Terni, Oct 9, 2019
128. 'Implicazioni sulla ricerca clinica delle innovazioni tecnologiche in radioterapia: il progetto della Proton Therapy' IRCCS: ISTITUTO NAZIONALE TUMORI "REGINA ELENA" 18 MAGGIO 2019 SEMINARIO RESIDENZIALE: PIANO STRATEGICO DELLA RICERCA E INTEGRAZIONE RICERCA-ASSISTENZA, Frascati (Rome), May 18, 2019
129. 'Caratteristiche peculiari dei tumori delle ghiandole salivari'. Contouring delle neoplasie ghiandole salivari del distretto testa collo. Airo course on contouring salivary gland tumors. Rome, Oct 25, 2019
130. 'Moderate Hypofractionation: a new standard regimen'. ADVANCE IN RADIATION ONCOLOGY: EXPERT MEETING. Pontremoli (PI), Oct 25, 2021
131. 'Stato dell'arte nel trattamento chemioradioterapico del NSCLC localmente avanzato: il punto di vista del radioterapista'. La strategia terapeutica nel trattamento delle neoplasie, Camogli (GE), Nov 22, 2019
132. 'Modelli predittivi in SBRT'. Space OAR user meeting Italia, Bologna, Nov 27, 2019
133. 'TREATING PROSTATE CANCER: SBRT INDICATIONS AND TECHNIQUES' INTERACTIONS BETWEEN NEW SYSTEMIC THERAPIES AND STEREOTACTIC RADIATION TREATMENTS, Rome, dec 14, 2019
134. 'Radioterapia: adiuvante vs salvataggio'. URO-ONCOLOGY FIGHT CLUB: DILEMMAS IN URO-ONCOLOGY. Oct 9, 2020
135. 'SBRT nell'early NSCLC'. LA GESTIONE MULTIDISCIPLINARE DEL NSCLC. Rome, Nov 25, 2020
136. 'Il Punto di vista del Radioterapista: indicazioni alla reirradiazione ONCOLOGIA CHIRURGICA, MEDICA E RADIOTERAPICA 2020: NEURO-ONCOLOGIA ED ONCOLOGIA TORACICA. Naples, Nov 27, 2021
137. 'Le domande per l'oncologo e per il radioterapista'. Il trattamento multidisciplinare dei tumori del distretto testa-collo: un approccio pratico. Webinar, Jan 20, 2021
138. 'TRATTAMENTO DEI TUMORI POLMONARI' Webinar, Dec 18, 2020
139. 'IL PAZIENTE CON MALATTIA LOCALMENTE AVANZATA'. Il diritto alle cure del paziente con carcinoma del polmone durante la pandemia da Covid-19. Webinar, Feb 23, 2021
- 140 'Dai patterns of failure alle Linee Guida di Contouring'. CORSO DI FORMAZIONE A DISTANZA SUL CONTOURING DELLE NEOPLASIE DEL RINOFARINGE Barletta, Oct 29, 2021
141. 'Dai patterns of failure alle Linee Guida di Contouring'. CORSO DI FORMAZIONE A DISTANZA SUL CONTOURING DELLE NEOPLASIE DEL RINOFARINGE Rome, June 4th, 2021
142. 'Role of the multidisciplinary team' (roundtable). Management of spinal metastases, Milan, April 16, 2021
143. ' Strategie emergenti nel trattamento combinato dei tumori laringei in stadio intermedio-avanzato: quali sono le prospettive?' (Roundtable). Sio, Milan, May 26, 2021
144. 'Impatto dei nuovi fattori prognostici sui tumori della lingua' (Roundtable). Sio, Milan, May 29, 2021
145. 'Approccio innovativo in radioterapia per il trattamento del NSCLC' All together per la patologia polmonare, Rome, June 10, 2021
146. 'Current innovative radiation strategies'. EMERGING TOPICS AND DEBATED ISSUES IN BREAST CANCER. Rome, June 18, 2021
147. 'Le prospettive dell'oncologo radioterapista nella gestione clinica del paziente oligoricorrente: one size fits to all?' QUESITI APERTI NELLA GESTIONE DEL PAZIENTE CON CARCINOMA PROSTATICO. Webinar, Sept 14, 2021
148. 'Radioimmunoterapia nel trattamento dei tumori testa e collo'. Radioterapia di precisione e immunoterapia, Pesaro, Oct 1st, 2021

Internazionali

1. "Radiochemotherapy for head and neck carcinoma". 1st world congress on head and neck oncology. Dec 2, 1998, Madrid, Spain
2. "Chemotherapy in association with radiotherapy. Tolerancy. Indications". 1st world congress on head and neck oncology. Dec 3, 1998, Madrid, Spain
3. "Chemoradiotherapy for head and neck tumors". University of Texas Medical Branch (UTMB) at Galveston, October 16, 1999
4. "Determination of CTV and PTV for Head and Neck tumors". ESTRO Teaching Course on "Imaging for target volume determination in radiotherapy", Como, Italy, 9–13 April 2000
5. "General aspects of radiotherapy". First international conference on oncology. Tripoli, Libia, May 27, 2000
6. "Clinical issues for IMRT" Southwest Chapter AAPM Spring Meeting, Houston, 3/28/03
7. "Uncertainties in clinical target volume definition" 7th biennial ESTRO meeting on physics and radiation technology for clinical radiotherapy. Geneva (Switzerland), September 16, 2003
8. "Current Strategies for cancer of the Prostate: Radiotherapy" Christus St Joseph Hospital, Houston, July 14, 2004
9. "Volume and dose/volume constraints for HN and GU cancers". IMRT course, Galveston, December 9, 2005
10. "IMRT for oropharyngeal carcinoma". Mid-Atlantic Society of Radiation Oncologist,, Baltimore, September 29, 2007
11. "SCORING TOXICITY: IMPROVING OBJECTIVITY FOR PRECISE DOSE-VOLUME MODELING" ESTRO pre-meeting course, DOSE-VOLUME RESPONSE RELATIONSHIPS IN NORMAL TISSUES. Goteborg, Sweden, Sept 14, 2008
12. "Re-irradiation for HN cancer" Great Baltimore Medical Center, Baltimore, MD, Feb 20, 2009
13. "Role of radiotherapy in the management of Thyroid Cancer". Course on Thyroid Cancer. Johns Hopkins University, Baltimore, July 17, 2009
14. Adaptive RT in HN cancer". 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy", Maastricht, Sept 2, 2009
15. "Treatment de-intensification for oropharyngeal cancer". ASTRO, Chicago, IL, Nov 4, 2009
16. "Current limiting toxicities of non surgical treatment and perspectives". Upgrades on HPV-associated Head and Neck Cancer. Baltimore, October 16, 2010
17. "Best of Astro: Head and Neck". Best of Astro, University of Maryland, Baltimore, January 6th, 2010
18. "ASSESSMENT OF HEAD-NECK TOXICITY USING CT" ESTRO 31, 11 May 2012, Barcelona, Spain
19. "This House Believes That Concurrent Chemoradiation is the Standard of Care in Advanced laryngeal and Hypopharyngeal Cancer. In Favour". ECCO 2013, Amsterdam, 29 Sept 2013
20. "Parotid deformation during IMRT correlates with clinical and dosimetry information". ECCO 2013, Amsterdam, 1 Oct 2013
21. "De-intensification of radiation". 4th IAOO Rhodes Italian Society of ENT Surgery sponsored symposium. Rhodes, May 15, 2013
22. "Radiotherapy for oropharyngeal cancer". Instite Gustave Roussy, Paris, March 13, 2014 (visiting professor)
23. "Consensus Conference on salivary gland tumors - Adenoid-cystic carcinoma and high-grade malignancies" Brescia (Italy), October 23rd–24th 2014
24. "Radiotherapy for high risk prostate cancer: where do we stand?" 3rd Global Congress on Prostate cancer. Rome, 5 febbraio 2015
25. "Evolution of radiotherapy target volumes in head and neck cancer". Innovation and paradigms in head and neck cancer - Poznan (Poland), May 13, 2016
26. "La Radioterapia nei tumori dei seni paranasali". 12° International SVO Conference on head & neck cancer -29-30 giugno/1-2 luglio 2016 - Mestre
27. "Management of oropharyngeal cancer". European Head and Neck Course, Milan Nov 17–18, 2016
28. "Organ preservation in laryngeal and hypopharyngeal cancer" European Head and Neck Course, Milan Nov 17–18, 2016
29. "Radiotherapy for oropharyngeal cancer" American University Beirut, Lebanon, March 16, 2018 (visiting professor)
30. "Radiotherapy for prostate cancer" American University Beirut, Lebanon, March 17, 2018 (visiting professor)
31. "Closing remarks", Advances in technology and innovation treatment in Head and Neck cancer, 8th European Congress on Head and Neck Oncology, Rome April 11, 2018
32. "Radiotherapy for Localized Prostate Cancer and Radiotherapy for Nasopharyngeal Cancer". The Affiliated Hospital of Guizhou Medical University in Guizhou, August 12, 2019 (Sino-Italian Medical Humanities Exchange Workshop)
33. "Radiotherapy for Localized Prostate Cancer and Radiotherapy for Nasopharyngeal Cancer". Shaanxi Provincial People's Hospital in Xi'an, August 14, 2019 (Sino-Italian Medical Humanities Exchange Workshop)
34. "Radiotherapy for Localized Prostate Cancer and Radiotherapy for Nasopharyngeal Cancer". General Hospital of Ningxia Medical University in Yinchuan, August 16, 2019 (Sino-Italian Medical Humanities Exchange Workshop)
35. "Implications of the 2017 TNM staging for oral and oropharyngeal cancer 7th World Congress of the International Academy on Oral Oncology Rome Sept 1, 2019
36. "Surgery based treatment vs. radiation based treatment for stage III (7th AJCC) oropharyngeal cancers" 7th World Congress of the International Academy on Oral Oncology Rome Sept 1, 2019
37. "Predictive models: HN". Predictive models in external beam radiotherapy. Naples, March 26, 2019
38. "Radiation Treatment of oropharyngeal tumors". 13rd International SVO Conference on Head and Neck Tumors. Mestre (VE), June 22, 2019
39. "The anterior skull base- clinical cases" (round table). 13rd International SVO Conference on Head and Neck Tumors. Mestre (VE), June 21, 2019

40. "Management of early stage larynx cancer". 6th world congress of the International Federation of Head and Neck Oncologic Societies, Buenos Aires, Sept 3, 2018
41. "Oropharyngeal Cancer". IFHNOS World Tour, Milan Nov 5, 2018
42. "The role of hydrogel spacing in hypofractionated radiotherapy for prostate cancer". ICRR meeting 2019, Manchester, August 27, 2019
43. 'Stereotactic Radiotherapy for prostate cancer'. 20th pan arab cancer congress, Amman (Jordan), March 12, 2021

OTHER PROFESSIONAL ACCOMPLISHMENTS

Conference (Oral) Presentations

Italy:

1. "Ruolo del Simulatore TC nella Radioterapia dei Tumori della Testa e del Collo" (Role of CT simulator in radiotherapy of HN tumors). I nuovi volti della Radiologia – Oct 8, 1989, Rapallo (Genoa, Italy)
2. "Vantaggi di un TC Simulatore per il posizionamento del paziente e l'esecuzione di un trattamento radioterapico" (Advantages of a CT Simulator in the positioning and treatment of patients undergoing radiotherapy). X Congresso Nazionale della Sezione Autonoma di Radioterapia Oncologica (S.A.R.O.) and VII Convegno Nazionale della Sezione Autonoma di Fisica Sanitaria, Oct 19, 1989, Montecatini Terme (Italy)
3. "Studio e verifica automatica di campi di forma irregolare con un TC Simulatore" (Planning and simulation of irregular fields with a dedicated CT simulator). X Congresso Nazionale della Sezione Autonoma di Radioterapia Oncologica (S.A.R.O.) and VII Convegno Nazionale della Sezione Autonoma di Fisica Sanitaria, Oct 20, 1989, Montecatini Terme (Italy)
4. "Pianificazione dei trattamenti Radioterapici con TC Simulatore"(Treatment planning with a CT Simulator). VII Congresso Nazionale di Tecnologie Avanzate, Oct 27, 1989, Cagliari (Italy)
5. "La prevenzione dei danni odontostomatologici radio-indotti: presentazione di un nuovo protocollo clinico-terapeutico". (Prevention of radiation-induced dental complications: new protocol). XVII Giornate di Rinnovo Medico Odontoiatrico, Sat 11, 1989, Santa Margherita Ligure (Genoa, Italy)
6. "Una proposta tecnica per il trattamento della mammella e dei linfonodi regionali in pazienti affette da neoplasia operate conservativamente" (A new technique to treat the breast and regional lymphatics after breast-conserving surgery). Convegno Internazionale di Fisica e Radioterapia Oncologica, Elettroni di alta energia, Nov 30, 1990, Ospedali Galliera-Genoa (Genoa, Italy)
7. "Tecnica radioterapica con collimatori asimmetrici: indicazioni cliniche e vantaggi"(Asymetric jaws in radiotherapy: indications and advantages) VIII Congresso nazionale della federazione nazionale collegi tecnici sanitari di radiologia medica. Oct 18, 1991, Cittadella di Assisi (Perugia, Italy)
8. "Radiotherapy of advanced esthesioneuroblastoma". 4th European Congress on Dental and Maxillofacial Radiology. June 12, 1993, Torino (Italy)
9. "Radioterapia accelerata nei carcinomi squamosi della testa e collo: risultati preliminari"(Accelerated radiotherapy for HN-SCC: preliminary results). II Convegno della Sezione Ligure della Società Italiana di Radioterapia Oncologica. July 3, 1993, Genoa (Italy)
10. "Radiosensibilità intrinseca e radioterapia: implicazioni cliniche e problematiche"(Intrinsic radiosensitivity and radiotherapy: problems and clinical implications). XX Congresso Nazionale di Radiobiologia. Sept 29, 1993, Rome (Italy)
11. "Radioterapia post-operatoria per carcinomi squamosi della testa e collo: fattibilità di un trattamento accelerato bifasico"(Biphasic accelerated radiotherapy in the postoperative treatment of HN-SCC: feasibility) XIX Congresso Nazionale SICO, March 12, 1995, Florence (Italy)
12. "Radioterapia accelerata secondo la tecnica del supplemento di dose concomitante per neoplasie della testa e collo: esperienza di Genova"(Accelerated radiotherapy according to the concomitant boost technique: the experience of Genoa). Il frazionamento alterato della dose in radioterapia. Esperienze a confronto. II Riunione di studio. June 14, 1997, Cremona (Italy)
13. "Fattori prognostici in pazienti affetti da carcinoma vescicale infiltrante vescica trattati con chemioradioterapia alternata"(Prognostic factors in patients affected by invasive bladder cancer undergoing alternating radiochemotherapy). VIII Congresso nazionale AIRO, Nov 25, 1998, Milano (Italy)
14. "Associazione ormonoterapia radioterapia conformazionale ad alta dose nel carcinoma prostatico localizzato"(Hormonal manipulation and conformal radiotherapy in localized prostate carcinoma). VIII Congresso nazionale AIRO, Nov 26, 1998, Milano (Italy)
15. " Does chemotherapy dose-density adversely affect radiotherapy dose-intensity after breast-conserving surgery?" I Congresso AIOM, Roma, 27 Ottobre 1999

International:

1. "Treatment elapsed days in accelerated radiation therapy schedules: a crucial factor". Clinical Trials in Oncology: Improving their design and analysis. Oct 28, 1993, Toronto (Canada)
2. "Association of in vivo cell kinetics and tumor regression during radiotherapy with prognosis in HN-SCC". 4th International Conference on Head and Neck Cancer. August 31, 1996, Toronto (Canada)

3. "Cell kinetics analysis by in vivo bromodeoxyuridine and flow-cytometry in advanced head and neck tumors treated by conventional radiotherapy", IVth Research workshop. Biology, Prevention, and Treatment of Head and Neck Cancer, Sept 8, 1994, Arlington, Virginia (USA)
4. "Predictive factors of outcome in invasive bladder cancer treated by alternating chemoradiotherapy". Gilbert Fletcher Society. 22nd annual meeting. June 13-23, 1997 Barcelona (Spain)
5. "Is planned neck dissection indicated if chemotherapy is added to 60 Gy?". International symposium on metastases in head and neck cancer, Jan 16, 1998, Kiel (Germany)
6. "Accelerated radiotherapy for the postoperative treatment of advanced head and neck carcinoma: long term results". Paris, November 26, 1999
7. "Rectal toxicity after conformal radiotherapy for localized prostate cancer". Berlino, May 13, 2000
8. "Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy". 43 Astro meeting, S Francisco, November 4, 2001
9. "Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: preliminary results of a multicenter phase III study". 21st annual ESTRO meeting, Prague, Sept 21, 2002.
10. "Androgen deprivation and late rectal bleeding after radiotherapy for prostate carcinoma". 44th Astro meeting, New Orleans, Oct 9, 2002
11. "Accelerated hyperfractionated intensity modulated radiotherapy for T2-3 oropharyngeal carcinoma. Preliminary results from a phase I-II study". ICRT 2006, Third International Conference on Translational Research and Preclinical Strategies in Radiation Oncology, Lugano, Switzerland, March 15, 2006
12. "Dosimetric predictors of laryngeal edema". 48th Annual Meeting ASTRO, November 7, 2006, Philadelphia, PA
13. "Effect of radiotherapy and chemotherapy on the risk of mucositis during IMRT for oropharyngeal cancer". American Head and Neck Society 2010 Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer. Arlington, (VA), October 29, 2010
14. "Defining the Risk of Involvement for Each Neck Nodal Level in Patients with Early T-stage/Node-Positive/HPV-related Oropharyngeal Carcinoma" 53rd Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), Miami beach (FL), Oct 3 2011
15. "Hypo Vs Conventionally Fractionated 3dcr for High Risk Prostate Cancer: Updated Results of a Randomized Trial". 56th Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), San Francisco (CA), Sept 16, 2014
16. "MACROSCOPIC HEMATURIA AFTER CONVENTIONAL OR HYPOFRACTIONATED RADIOTHERAPY: RESULTS FROM A PROSPECTIVE PHASE III STUDY" 57th Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), San Antonio (TX), Oct 20, 2015
17. "Double Blind Randomized Phase III Study Comparing a Mixture of Natural Ingredients vs Placebo in the Prevention of Acute Mucositis During Chemoradiotherapy for Head and Neck Cancer" 57th Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), San Antonio (TX), Oct 21, 2015
18. "Impact of sequencing radiotherapy and chemotherapy on long-term local toxicity for early breast cancer: results of a randomized study at 15 yr follow up". 57th Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), San Antonio (TX), Oct 21, 2015
19. "Prediction of Treatment Response of Cervical Nodes Using IVIM-DWI". 58th Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), Boston (MA), Sept 27, 2016
20. "Short-Course Hypofractionated Whole-Breast Radiation Therapy After Conservative Surgery: A Single-Institution Prospective Study". 58th Annual Meeting sponsored by the American Society for Radiation Oncology (ASTRO), Boston (MA), Sept 27, 2016
21. "Early Radiation-Induced Changes of Parotid Glands at Intravoxel Incoherent Motion and Dynamic Contrast-Enhanced MRI". ASTRO's 59th Annual Meeting. San Diego (US) Sept 26, 2017
22. "The role of hydrogel spacing in ultrahypofractionated radiotherapy for prostate cancer" ESTRO38 Luncheon Satellite Symposium Prostate Radiation Therapy Dose Escalation with SpaceOAR™ Hydrogel Spacing, April 29, 2019
23. "The Predictive Role of multiparametric MR imaging after Salvage Radiation Therapy for Local Failure after Radical Prostatectomy". ASTRO 60th Annual meeting, San Antonio, Oct 21, 2018